



April 28, 2006

Mr. Edward Hammond, Director  
The Sunshine Project  
P.O. Box 41987  
Austin, TX 78704

Re: Public Record Request No. 06-042 Received March 15, 2006

Dear Mr. Hammond:

Enclosed is our response to your Public Records Request ("PRR"). Your payment for the responsive records and our closing letter, also dated April 28, 2006, crossed in the mail this morning. Please disregard the closing letter.

No documents have been withheld from this response pursuant to any claim of exemption under the Public Records Act ("PRA"); however, the student identifiers have been redacted (deleted/concealed) from education records. The statutory basis for the redactions is 20 USC § 1232g of the Family Educational Rights and Privacy Act ("FERPA"), which ensures the confidentiality of student identifiers.

This concludes the University's response to your request for public records.

If you have any questions or comments, please feel free to contact me at 509-335-2004 or Linda Nelson at 509-335-3928.

Very truly,

A handwritten signature in black ink, appearing to read "Ralph Jenks", with a long horizontal line extending to the right.

Ralph Jenks  
Public Records Officer

Enclosure

**PUBLIC RECORDS RESPONSE**

RCW 42.17

See 90.05 for additional instructions.

Washington State University  
Office of Procedures, Records and Forms  
Information Technology Building 3089  
Pullman, WA 99164-1225  
(509) 335-3928  
FAX (509) 335-3969  
E-mail forms@mail.wsu.edu

**REQUEST NUMBER**

8-42

**DEPARTMENT**

Biosafety

**DATE OF REQUEST**

March 15, 2006

**RESPONSE DUE**

April 28, 2006

The University has received a public records request for records meeting the following description. Please provide the following records to the Public Records Officer.

**REQUEST DESCRIPTION**

Minutes of all meetings of the WSU Institutional Biosafety Committee since May 1, 2003.

*No IBC Mtgs held May 2003 and Aug 2003.*

**Additional Information:**

The following fields are completed by the responding department:

I searched for records in the following locations:

I requested records from the following individuals:

I am submitting the following records to the Public Records Officer: *all IBC minutes since May 1, 2003 to present*

☐ *< 1 Hr*

Estimate of time in hours expended to compile responsive records.

If additional records meeting the above description may be found in other departments, please identify departments and provide contact names.



No requested records were found.

I hereby state that I conducted a diligent and good faith search of the files and records for the requested records. To the best of my knowledge, information, and belief, I have provided all such records to the University Public Records Officer as of the date indicated below. I specifically state that I am aware of no other documents responsive to this public records request that have not been provided and I have no reason to believe that any such document exists.

I understand that this statement will be filed with the court if an action arises and that the court will rely on this statement as truthful.

**NAME OF RESPONDER**

*Lorraine A. McConnell*

**SIGNATURE OF RESPONDER**

*Lorraine A. McConnell*

**DATE OF RESPONSE**

*March 21, 2006*

*105 pgs  
\$15.75  
\$4.05 / 116 603*

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**June 2, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Mary Sanchez-Lanier (chair), Tim Baszler, Kwan Hee Kim, Mike Kluzik, David Clark, Dan Bradway, Dan Nordquist, Misty Cato  
**ABSENT:** Linda Thomashow, Farol Tomson  
**GUEST:** Rob Corcoran

**1. MINUTES – April 28, 2003**

**Changes to Minutes:** Motion on item 3.A.1 was seconded by F. Tomson, not D. Bradway. Summary of discussion on item 4.A.4; for the project titled, "*knockouts and signature-tagged mutagenesis of E. coli*," will be adjusted to clarify that calves used for the tet(B) knockout experiment could be sold at market at the conclusion of the experiment. Innoculated animals should be rendered and/or incinerated.

**Motion to approve with changes by K.H. Kim, 2<sup>nd</sup> D. Bradway and approved 7:0.**

**2. BSL-1 MUAs**

**A. New Protocols/Modifications**

1) *Development of recombinant ovalbumin-LHRH vaccine to sterilize heifers* Reeves, J.  
**Motion to approve by D. Bradway, 2<sup>nd</sup> by K.H. Kim and passed (7:0).**

2) *Molecular and Biological Approaches to Studying Emerging Virus Threats* Pappu, H.R.

**Summary of Discussion:** L. Thomshow was unable to attend the meeting, but she did review this protocol and found no issues of concern.

**Motion to approve by K.H. Kim, 2<sup>nd</sup> by T. Baszler and passed (7:0).**

**4. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Recombinant potential of West Nile virus and Saint Louis Encephalitis virus* Borucki, M.

**Summary of Discussion:** This protocol involves non-infectious RNA segments which do not require BSL-2 or 3 containment. The researcher is choosing to use BSL-2 facilities and procedures for this material due to the public perception of West Nile.

**Motion to approve as a BSL-1 protocol by D. Bradway, 2<sup>nd</sup> by K.H. Kim and passed 7:0.**

2) *Retroviral transfection of bovine germ cells* Reeves, J.

**Summary of Discussion:** Innoculated animals can be housed in BSL-1 facilities because once the nucleic acid is in the animal it can not replicate and is not infectious.

**Motion to approve by T. Baszler, 2<sup>nd</sup> by K.H. Kim and passed 7:0.**

### *3) Regulation of Human Milk Fat by Diet and Adiposity*

McGuire, S.

**Summary of Discussion:** This MUA is for research currently going on, in which the researcher did not know an MUA is required. The MUA is incomplete for the following reasons:

- Facility needs to be inspected and certified
- Blood Borne Pathogen plan and training must be in place
- Methods must be described in greater detail
- Project has no title

**Motion to defer** pending receipt of a completed submission within a week by T. Baszler, 2<sup>nd</sup> by D. Clark and passed 7:0.

**Continuing Discussion:** There was considerable concern that this research is ongoing with no evidence that the researcher and research team are taking the necessary precaution to handle human blood. The committee discussed asking the research to stop all research procedures involving human fluids until the MUA is approved, but several on the committee felt there wasn't enough evidence of dangerous procedures to halt the research, particular without allowing the Dr. McGuire an opportunity to respond to the committee's concerns. The committee asked M. Kluzik and D. Clark to visit Dr. McGuire's lab at the earliest opportunity to make judgment regarding the currently safety of the lab and make arrangement to provide blood borne pathogen training.

**Motion to allow for the continuation of Dr. McGuire's research pending** M. Kluzik and D. Clark finding that current laboratory practices and procedure pose no immediate threat to researcher staff by D. Bradway, 2<sup>nd</sup> by D. Nordquist and passed 7:0.

## **5. OLD BUSINESS**

**A. Subcommittee Report:** The subcommittee has recommended hiring a biosafety officer and is working on a proposed structure of the oversight of biosafety activities. The Vice Provost for Research is establishing a couple of committees to look into biosafety on campus and the IBC report will be important for them to look over. Dan Bradway and Tim Baszler agree to serve as the IBC representatives to the Vice Provost's biosafety committee.

**B. Eastlick Facility:** Currently on hold pending decisions to be made by the Vice Provost's committee of BSL-3 facilities.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**July 28, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Mary Sanchez-Lanier (chair), Tim Baszler, Mike Kluzik, David Clark, Dan Bradway, Dan Nordquist, Lorraine McConnell, Farol Tomson, Chris Baylon (alternate to Mike Kluzik)

**ABSENT:** Kwan Hee Kim, Misty Cato, Linda Thomashow

**EX-OFFICIO:** Rob Corcoran

**1. MINUTES – June 2, 2003**

**Motion to approve 7:0.**

**2. BSL-1**

**A. New Protocols/Modifications**

1) *FSH and Retinoid Signaling in the Testis* Kim, K.H. 533

**Motion to approve by D. Bradway, 2<sup>nd</sup> by T. Baszler and passed 8:0.**

**B. Renewals**

1) *Sequencing and Cloning of Canine and Feline Trefoil Peptides* Campbell, B. 717

2) *The role of Babesia bovis merozoite surface antigen – 1 in erythrocyte invasion* [REDACTED] 728

**Motion to approve 1 and 2 by T. Baszler, 2<sup>nd</sup> by D. Bradway and passed 8:0.**

3) *Crab Shell Chitosan as a Pesticide Sticker and Immune Response Activator* Hadwiger, L. 549

**Motion to approve pending comments from L. Thomashow by D. Bradway, 2<sup>nd</sup> by T. Baszler and passed 8:0.**

**3. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Isolating listeria monocytogenes from Dairy Cattle and Their Environment* Fox, L. 818

**Motion to approve pending facility review and approval of biosafety manual from EH&S by T. Baszler, 2<sup>nd</sup> by D. Bradway and passed 8:0.**

2) *EIAV Control by High Avidity Rev-Specific CTL Clones* Mealey, R. 559

**Summary of Discussion:** Dr. Mealey needs to be added laboratory biosafety manual.

**Motion to approve by T. Basler, 2<sup>nd</sup> by D. Nordquist and passed 8:0.**

**B. Renewals**

1) *Mechanism of TCDD Pulmonary Immunotoxicity/Effects of prenatal exposure to dioxin on lymphocyte function and immunological memory* Lawrence, B. 590

**Motion to approve pending verification of the VSV strain by T. Baszler, 2<sup>nd</sup> by F. Tomson and passed 8:0.**

#### **4. OLD BUSINESS**

**A. Update on S. McGuire Lab:** Mike Kluzik and Dave Clark visited Dr. McGuire's lab on June 3, 2003 and verified proper equipment and lab requirements for BSL-2 certifications were in place. Lab personnel are working with EH&S on their lab biosafety manual. Blood Borne Pathogen Training was completed within days. The committee agreed to extend conditional approval pending receipt of new MUA for September meeting.

**B. Use of Human Tissue and Fluids in Research:** OGRD has revised the section concerning infectious agents on the REX form to include blood and bodily fluids.

#### **5. NEW BUSINESS**

**A. Letter to Greg Royer:** EH&S plans to take biosafety as a budget reduction. Mary Sanchez-Lanier recommended the committee send a letter to Greg Royer stressing the importance of EH&S continued involvement in biosafety.

Motion for chair to write letter as described passed 7:0, M. Kluzik abstaining.

**B. Selection of new chair:** Mary Sanchez-Lanier has completed her term as chair and is rotating off the committee. Tim Baszler was nominated and voted in as new chair.

**C. Nominations of new committee members:** Kwan Hee Kim has completed her term of service and is rotating off the committee. No nominations were made for new members.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**September 29, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Mike Kluzik, Farol Tomson, Daniel Bradway, Dave Clark, Dan Nordquist, Chris Baylon, Robert Bogden, [REDACTED]

**ABSENT:** Linda Thomashow, Lorraine McConnell, Rob Corcoran

**1. MINUTES – July 28, 2003**

**Motion to approve 8:0.**

**2. BSL-1 MUA's**

**A. New Protocols/Modifications**

1) *Biochemistry of Oil Seeds: New Strategies for Improving Oils* Browse, J. 826

**Motion to approve** by D. Bradway, 2<sup>nd</sup> by D. Clark and passed 8:0.

2) *Johne's Disease Integrated Program* Davis, W. 825

**Motion to approve** as BSL2 & ABSL2 pending review of facilities, and review of the biosafety manual by D. Bradway, 2<sup>nd</sup> by D. Clark and passed 8:0.

**B. Renewals**

1) *Identification of T-cell Immunogens in Anaplasma* Brown, W. 766

**Motion to approve** by D. Bradway, 2<sup>nd</sup> by F. Tomson and passed 8:0.

**3. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Modulation of Immune Responses to CAEV SU* Trujillo, J. 832

**Motion to defer** decision pending [REDACTED] contacting the PI to have them submit a new MUA by D. Clark, 2<sup>nd</sup> by F. Tomson and passed 8:0.

2) *Immune Control of CAE Lentivirus* Cheevers, W. 831

**Motion to defer** decision pending [REDACTED] contacting the PI to have them submit a new MUA by D. Clark, 2<sup>nd</sup> by F. Tomson and passed 8:0.

3) *Effect of Maternal Conjugated Linoleic Acid (CLA)* McGuire, S. 830

*Consumption on Milk Fat: Collection of Milk for Microarray Analysis*  
**Motion to defer** pending clarification of which procedures are being done in which rooms and also clarification of the procedures for drawing blood and centrifuging by [REDACTED] 2<sup>nd</sup> by D. Nordquist and passed 8:0. There was also a strong recommendation that serum banking be offered

4) *Relationships Among Vitamin B-6 Intake, B-6 Status Measures, and In Vitro and In Vivo Immune Responses of Young and Older Men and Women* Shultz, T. 829

**Motion to approve** procedures to be done in rooms FSHN 248 & FSHN 289 with the understanding that after centrifuging, opening of vials or manipulation of samples occurs in room

248 and/or 289, and there was a strong recommendation that serum banking be offered by D. Bradway, 2<sup>nd</sup> by F. Tomson and passed 8:0

5) *Lysophosphatic Acid in Overian Cancer*

Meier, K. 828

**Motion to approve** pending room approval, and there was a strong recommendation that serum banking be offered by D. Bradway, 2<sup>nd</sup> by D. Clark and passed 8:0.

B. Renewals

1) *CTL Effectors in Bovine Congenital Neosporosis*

Staska, L. 699

**Motion to approve** by D. Bradway, 2<sup>nd</sup> by F. Tomson and passed 8:0.

4. BSL-3 MUA's

A. New Protocols/Modifications

1) *National Animal Disease Diagnostic Network*

McElwain, T. 824

**Motion to approve** pending approval of facility by EH&S by F. Tomson, 2<sup>nd</sup> by R. Bogden and passed 8:0.

2) *Biology of ruminant gammaherpesviruses associated with malignant catarrhal fever*

Knowles, D. 823

**Motion to approve** pending approval of facility by EH&S by F. Tomson, 2<sup>nd</sup> by R. Bogden and passed 8:0.

5. Old Business

6. New Business

- A. Discuss a proposal to review transgenic plant procedures. It was decided to discuss this at our next IBC meeting.
- B. The Presidential Committee website regarding the IBC needs to be updated. A draft was handed out to the member of the committee and they were asked to contact [REDACTED] with updates to this information by Friday, October 3<sup>rd</sup>.



**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**October 27, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Mike Kluzik, Farol Tomson, Daniel Bradway, Dave Clark, Dan Nordquist, Chris Baylon, Robert Bogden, Linda Thomashow, Rob Corcoran

**ABSENT:** Lorraine McConnell, [REDACTED]

**1. MINUTES – September 29, 2003**

**Motion to approve 8:0.**

**2. BSL-1 MUA's**

**A. New Protocols/Modifications**

1) *Generation of babesial surface protein diversity* Berens, S. 833

**Motion to approve by D. Bradway, 2<sup>nd</sup> by D. Nordquist and passed 8:0.**

**B. Renewals**

1) *Apical intestinal membrane proteins of nematodes* Jasmer, D. 712

**Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Bradway and passed 8:0.**

**3. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Can Phytoestrogens Improve Memory in Healthy Menopausal Women* Beerman, K 835

**Motion to approve pending PI contacting EH & S regarding vaccinations being required under bloodborne pathogen standard by L. Thomashow, 2<sup>nd</sup> by F. Tomson and passed 8:0. Serum banking was recommended**

**B. Renewals**

None

**4. BSL-3 MUA's**

**A. New Protocols/Modifications**

None

**5. Old Business**

None

**6. New Business**

**A.** We will be starting to assign primary and secondary reviewers to the MUA's. It was noted that all committee members should still read each protocol. Both the primary and secondary reviewers should do a thorough review. The primary reviewer should be the only one contacting the PI. The primary reviewer should be prepared to explain the MUA in detail.

**B. Tim Baszler announced that there would be Pre-IBC meetings held to assist in making the meetings run smoother. The members that will attend these meetings are the chair, Dave Clark, Mike Kluzik and [REDACTED]**

**C. Transgenic plants - Tim Baszler attended a CAHE meeting regarding transgenic plant issues at WSU. The IBC members felt they needed to be more of a part in this campus issue. Tim Baszler felt that we needed to create a subcommittee for this. The committee did not feel that this was needed, and that the committee could review MUA's with transgenic plants like they review other MUA's.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**November 17, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Farol Tomson, Dave Clark, Dan Nordquist, Chris Baylon, Robert Bogden, Rob Corcoran, [REDACTED]

**ABSENT:** Mike Kluzik, Daniel Bradway, Linda Thomashow, Lorraine McConnell

**1. MINUTES – October 27, 2003**

**Motion to approve with changes to item “C” in the New Business section of the minutes, passed 8:0.**

**2. BSL-1 MUA's**

**A. New Protocols/Modifications**

None

**B. Renewals**

- 1) *Comparative genomics for phenotype mapping of intracellular bacteria* Brayton, K. 730

**Primary Reviewer:** L. Tomashow

**Secondary Reviewer:** R. Bogden

**Motion to approve by Robert Bogden, 2<sup>nd</sup> by Dave Clark and passed 8:0.**

**3. BSL-2 MUA's**

**A. New Protocols/Modifications**

- 1) *Cell mediated immune mechanisms of cattle in response to hemoparasite infections* Goff, W.L. 836

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** D. Clark

**Motion to approve pending approval of manual and facilities by EH&S by Dave Clark, 2<sup>nd</sup> by Farol Tomson and passed 8:0.** Chris Baylon stated that the biosafety manual is being worked on by EH&S, and that the lab inspection was to be done on November 18, 2003. Chris also stated that Bustad 334 has not yet been approved for BSL2.

- 2) *The role of titin in the function of the heart*

Granzier, H. 837

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** D. Clark

**Motion to defer by [REDACTED], 2<sup>nd</sup> by Farol Tomson and passed 8:0.** The committee felt that this MUA was incomplete and needed to have more information before it could be considered for approval. The MUA did not have the chemical hygiene box checked, there was not a lot of detail in the abstract, under the health and safety section the blood borne pathogen section was not checked. EH&S is working with the PI on his manual, facilities and a blood borne pathogen plan.

**B. Renewals**

- 1) *Molecular Mechanisms of Sleep Responses to Viral Infections* Krueger, J. 528

**Primary Reviewer:** T. Baszler

**Secondary Reviewer:** F. Tomson

**Motion to approve by Farol Tomson, 2<sup>nd</sup> by Tim Baszler and passed 8:0.**

#### **4. BSL-3 MUA's**

None

#### **A. New Protocols/Modifications**

1)

#### **5. Old Business**

- A. Checklists – BSL2/BSL3:** Tim Baszler is working with Dan Bradway on this issue. He stated that the goal is to have checklists on the web so that PI's can see what the criteria are for BSL2 and BSL3 labs. The checklists would go over the basic hardware in the lab. Eventually there will be a draft of the checklist created.

#### **6. New Business**

- A. Criteria for 3 year renewal:** Farol recommended that we send out yearly notices to see if there are any changes or modifications to existing MUA's. Dave Clark mentioned that the MUA could be linked to the grants. Farol felt it was the responsibility of the PI to keep in compliance with their grant. Chris Baylon felt we needed a way to know when projects have been completed, and once that information is obtained, that it be forwarded to EH&S. Dan Nordquist stated that he could provide a list of people who have transferred grants. The committee recommended an annual letter be sent to PI's regarding renewal, modifications and termination of projects. A letter to Jim Peterson will be drafted noting these items.
- B. Serum Banking:** The committee discussed the issue of serum banking. It was noted that we don't have the infrastructure at this point to support serum banking, but the committee felt that this will be needed in the future. In the interim the IBC will recommend to PI's that they will need to determine if serum banking is needed for their project. This recommendation will be made until we have a Biosafety Officer who can assist with this issue. It was recommended that the Chair of the IBC send a letter to Jim Peterson regarding the fact that the IBC will be requiring or recommending serum banking for projects that might need it.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**December 15, 2003**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Farol Tomson, Dave Clark, Dan Nordquist, Chris Baylon, Rob Corcoran, Mike Kluzik, Lorraine McConnell, Daniel Bradway  
**ABSENT:** Robert Bogden, Linda Thomashow

**1. MINUTES – November 17, 2003**

**Motion to approve** with changes to item “A” in the New Business section of the minutes, by F. Tomson, 2<sup>nd</sup> by Dave Clark, passed 7:0. Dan Nordquist was not present during the vote. The change was to note that the MUA “could be linked to the grants”, instead of stating that it “needs to be linked.”

**2. ANNOUNCEMENTS**

It was announced that there has been a subcommittee formed that is working on the Biosafety Officer’s position description. This subcommittee has been named the Biosafety Officer/Biosafety Officer Roles & Responsibilities Sub-Committee.

**3. BSL-1 MUA’s**

**A. New Protocols/Modifications**

1) *Developing management strategies for plant viruses and virus-like agents that infect perennial vegetatively-propagated crop plants in the US (Project #WNP01262)* Eastwell, K. 839

**Primary Reviewer:** L. Tomashow

**Secondary Reviewer:** D. Clark

**Summary of Discussion:** It was discussed that the PI had been contacted and it was noted that there are no select agents being used.

**Motion to approve** by D. Clark, 2<sup>nd</sup> by F. Tomson and passed 8:0.

**B. Renewals**

None

**4. BSL-2 MUA’s**

**A. New Protocols/Modifications**

1) *Corn-barley mechanisms of bovine E. coli 0157 shedding* Hancock, D. 838

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** T. Baszler

**Summary of Discussion:** It was noted that section “F” of the MUA had not been filled out. The IBC Coordinator will contact the PI to have this filled out. EH&S stated that they will review the safety manual, but said it is ok to approve at this point.

**Motion to approve** pending completion of section “F” by D. Bradway, 2<sup>nd</sup> by D. Nordquist, and passed 8:0.

2) *The role of titin in the function of the heart*

Granzier, H. 837

Primary Reviewer: D. Bradway

Secondary Reviewer: D. Clark

**Summary of Discussion:** It was stated that a note be sent to the PI from the IBC Coordinator stating that it is the responsibility of the PI to determine the need for serum banking as per the CDC Manual, Appendix H page 234. A reminder that the Bloodborne Pathogen training still needs to be done will be mentioned in that same note from the coordinator.

**Motion to approve** pending the above mentioned note to be sent to the PI, by D. Bradway, 2<sup>nd</sup> by F. Tomson and passed 8:0.

B. Renewals

None

5. BSL-3 MUA's

A. New Protocols/Modifications

None

B. Renewals

None

6. Pending MUAs

- A) *Cell mediated immune mechanisms of cattle in response to hemoparasite infections* (Pending EH&S reviewing the manual and facilities – 11/18/03) Goff, W. 836

**Summary of Discussion:** EH&S stated that this is still in progress, and that it should stay on the agenda.

- B) *Johne's Disease Integrated Program* (Pending EH&S reviewing the manual and facilities – 10/15/03) Davis, W. 825

**Summary of Discussion:** EH&S reported that they have not heard back from the lab. A reminder to the PI will be sent by the IBC Coordinator on December 16, 2003. It will state that if we do not hear back from the PI within 30 days, the IBC will assume that the PI has withdrawn their MUA from further consideration.

- C) *Lysophosphatic Acid in Overian Cancer* (EH&S has reviewed the room & found discrepancies. EH&S is waiting on PI to respond back – 10/15/03) Meier, K. 828

**Summary of Discussion:** EH&S reported that they have not heard back from the PI. A reminder to the PI will be sent by the IBC Coordinator on December 16, 2003. It will state that if we do not hear back from the PI within 30 days, the IBC will assume that the PI has withdrawn their MUA from further consideration.

- D) *National Animal Disease Diagnostic Network* (Facility is under renovation. EH&S is waiting on PI to contact them – 10/15/03) McElwain, T. 824

**Summary of Discussion:** EH&S stated that they are still waiting on the autoclave to be installed, and that it is in process. No action is necessary at this point.

- E) *Biology of ruminant gammaherpesviruses associated with malignant catarrhal fever* (Facility is under construction. EH&S is waiting for the PI to contact them – 10/15/03) Knowles, D. 823

**Summary of Discussion:** EH&S is still waiting on the autoclave to be installed and that it is in process. No action is necessary at this point.

- F) *Crab Shell Chitosan as a Pesticide Sticker and Immune Response Activator* (Pending comments from Linda Thomashow. An email was sent to her on 8/14/2003) Hadwiger, L. 549

**Summary of Discussion:** The IBC Coordinator will pull this file to determine the action to be taken.

- G) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* (As per minutes of the October 22, 2002 meeting, this MUA was deferred pending further development of facilities and a more complete/detailed submission) Dahl, J. 788

**Summary of Discussion:** This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004.

## 7. Old Business

- A. Serum banking – A letter was sent to the Vice Provost of Research which has been attached to the minutes. It was discussed that boiler plates should be created regarding serum banking, so that it can be mentioned to PI's in their letters from the IBC Coordinator. These boiler plates will be reviewed by the committee during the January IBC meeting.
- B. Checklists – D. Bradway has emailed a list for T. Baszler to review. It was discussed that a checklist be created for PI's to use first, and then one should be created for EH&S and the Biosafety Officer to use when doing their inspections. The checklists should be put on the IBC website. It was also discussed that information regarding ventilation systems be on the checklists. These checklists are going to be used to create a better inspection process.
- C. IBC presidential website (update) – It was decided to hold off on making any changes at this point to the website until the Biosafety Officer/Biosafety Officer Roles & Responsibilities sub-committee has met.

## 8. New Business

- A. Tracking of transgenic organisms – D. Clark informed the IBC Committee of the need for tracking transgenic organisms. He mentioned that the College of Ag would like to send out a survey to see which transgenic organisms are currently on campus. He is currently working on this.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**January 26, 2004**  
**1:00-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Dave Clark, Chris Baylon, Rob Corcoran, [REDACTED], Mike Kluzik, Lorraine McConnell, Daniel Bradway, Robert Bogden, Linda Thomashow, Steven Russell

**ABSENT:** Dan Nordquist

**1. MINUTES – December 15, 2003**

**Motion to approve** by D. Clark, 2<sup>nd</sup> by M. Kluzik, passed 7:0.

**2. ANNOUNCEMENTS**

- A) Tim Bazler reported that the checklists for faculty members are still being worked on.
- B) Dave Clark reported that a search committee has been formed for the Biosafety Officer position.

**3. BSL-1 MUA's**

**A. New Protocols/Modifications**

1) *Alcohol and Retinoid Signaling in Testis Development*

Kim, K. 841

**Primary Reviewer:** Tim Baszler

**Secondary Reviewer:** Robert Bogden

**Motion to approve** by R. Bogden, 2<sup>nd</sup> by D. Bradway, and passed 8:0.

**B. Renewals**

None

**4. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Id gene expression in prostate cancer*

Chaudhary, J. 840

**Primary Reviewer:** Lorraine McConnell

**Secondary Reviewer:** Steve Russell

**Summary of Discussion:** EH&S reported that the blood borne pathogen plan, biosafety manual and the lab are being worked on.

**Motion to approve** pending EH&S review of the blood borne pathogen plan, biosafety manual and lab. Also pending verification that the PI is not using animals. This approval only includes room Abelson 506 as a BSL 2 lab by S. Russell, 2<sup>nd</sup> by D. Bradway, and passed 9:0.

**B. Renewals**

None

**5. BSL-3 MUA's**

**A. New Protocols/Modifications**



None

**B. Renewals**

None

**6. Pending MUAs**

- A) *Cell mediated immune mechanisms of cattle in response to hemoparasite infections* Goff, W. 836

**Summary of Discussion:** EH&S stated that the manual has been completed and the facilities are still under review.

- B) *Johne's Disease Integrated Program* Davis, W. 825

**Summary of Discussion:** EH&S reported that they are still working with the PI.

- C) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828

**Summary of Discussion:** EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue.

- D) *National Animal Disease Diagnostic Network* McElwain, T. 824

**Summary of Discussion:** EH&S stated that they are still working with the PI on this.

- E) *Biology of ruminant gammaherpesviruses associated with malignant catarrhal fever* Knowles, D. 823

**Summary of Discussion:** EH&S stated that they are still working with the PI on this.

- F) *Crab Shell Chitosan as a Pesticide Sticker and Immune Response Activator* Hadwiger, L. 549

**Summary of Discussion:** Linda Thomashow will review this MUA and will report back to the IBC coordinator.

- G) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788

**Summary of Discussion:** This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004.

**7. Old Business**

None

**8. New Business**

- A. IBC Meetings will be starting at 1:10pm beginning in February 2004.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**February 23, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (chair), Dave Clark, Rob Corcoran, [REDACTED], Mike Kluzik, Lorraine McConnell, Daniel Bradway, Robert Bogden, Linda Thomashow, Steven Russell  
**ABSENT:** Dan Nordquist, Chris Baylon

**1. MINUTES – January 26, 2004**

**Motion to approve by D. Clark, 2<sup>nd</sup> by R. Bogden, passed 6:0.**

**2. ANNOUNCEMENTS**

**3. BSL-1 MUA's**

**A. New Protocols/Modifications**

1) *Regulation of Gonadotropin Gene Expression* Nilson, J. 843  
**Primary Reviewer:** T. Baszler      **Secondary Reviewer:** D. Clark

**Motion to approve by T. Baszler, 2<sup>nd</sup> by D. Clark, and passed 6:0.**

2) *Probing the Protein and Cellular Function of the Paraveinal Mesophyll Cell Layer Using a Systems Approach* Grimes, H. 844  
**Primary Reviewer:** T. Baszler      **Secondary Reviewer:** D. Clark

**Motion to approve by T. Baszler, 2<sup>nd</sup> by R. Bogden, and passed 6:0.**

**B. Renewals**

None

**4. BSL-2 MUA's**

**A. New Protocols/Modifications**

1) *Immunogenicity of NAHV/ILT 295-149 against virulent Infectious Laryngotracheitis virus challenge following in ovo or subcutaneous inoculation in specific pathogen free chickens* Dhillon, A.S. 842  
**Primary Reviewer:** D. Bradway      **Secondary Reviewer:** T. Baszler

**Summary of Discussion:** The building being used has been approved by EH&S. The biosafety manual needs to be specific to the agent and the MUA. A draft of the manual has been sent to Mike Kluzik, but still needs to be updated.

**Motion to approve by T. Baszler, 2<sup>nd</sup> by L. Thomashow pending approval of the biosafety manual by EH&S, and passed 8:0.**

2) *Effect of Maternal Conjugated Linoleic Acid (CLA) Consumption on Milk Fat: Collection of Milk for Microarray Analysis* McGuire, S. 830  
**Primary Reviewer:** L. McConnell      **Secondary Reviewer:** M. Kluzik

**Summary of Discussion:** This item was not voted on due to the fact that it is a modification of a previously approved MUA.

B. Renewals

None

**5. BSL-3 MUA's**

A. New Protocols/Modifications

None

B. Renewals

None

**6. Pending MUAs**

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
As of 2/23/04, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue.
- B) *National Animal Disease Diagnostic Network* McElwain, T. 824  
(Facility is under renovation. EH&S is waiting on PI to contact them – 10/15/03)  
As of 2/23/04, EH&S reported that they are still working with the PI.
- C) *Biology of ruminant gammaherpesviruses associated with malignant catarrhal fever* Knowles, D. 823  
(Facility is under construction. EH&S is waiting for the PI to contact them – 10/15/03). As of 2/23/04, EH&S reported that they are still working with the PI.
- D) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
As of 1/26/2004, this MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004.
- E) *Id gene expression in prostate cancer* Chaudhary, J. 840  
As of 2/23/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab.

**7. Old Business**

- A. Dave Clark reported that he is still working with Jim Petersen and the AG's office about the transgenic plant survey.

**8. New Business**

- A. Revised MUA form: The revised MUA form was handed out to committee members. They were asked to review the form in the next few weeks and to get comments to the IBC Coordinator. The most current revision will be emailed to the members.
- B. Dave Clark informed the committee that there is an organization called the Sunshine Projects Group who has contacted IBC's registered with NIH and has asked for the last

two meeting minutes. Through the Freedom of Information Act, the group was given the WSU IBC meeting minutes for December of 2003, and January of 2004.

- C. Committee members commented that it would be good to have some type of sample biosafety manual available on the website for PI's to use when creating their manuals.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**March 29, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (Chair), Robert Bogden, Daniel Bradway, Dave Clark, Rob Corcoran, Mike Kluzik, Lorraine McConnell, Steven Russell, Linda Thomashow

**ABSENT:** Chris Baylon, [REDACTED], Hanu Pappu

1. **MINUTES** – February 23, 2004  
Motion to approve by L. Thomashow, 2<sup>nd</sup> by S. Russell, passed 7:0.

2. **ANNOUNCEMENTS**  
None.

3. **BSL-1 MUA's**

A. New Protocols/Modifications

- 1) *Does the wheat coronatine-insensitive1 homolog govern jasmonate-mediated defense in tomato roots?* Okubara, P. 845

**Primary Reviewer:** H. Pappu **Secondary Reviewer:** T. Baszler

Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 9:0.

- 2) *Transgenic Barley with Rhizoctonia Root Rot Resistance for Direct seed Cropping Systems* Wettstein, D 846

**Primary Reviewer:** L. Thomashow **Secondary Reviewer:** D. Bradway

Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 9:0.

- 3) *Transformation of microspores for generating transgenic wheat (Triticum aestivum L.)* Wettstein, D 847

**Primary Reviewer:** H. Pappu **Secondary Reviewer:** R. Bogden

Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 9:0.

- 4) *The role of Babesia bovis merozoite surface antigen – 1 in erythrocyte invasion* [REDACTED] 848

**Primary Reviewer:** T. Baszler **Secondary Reviewer:** D. Clark

Motion to approve by D. Bradway, 2<sup>nd</sup> by R. Bogden, passed 9:0.

- 5) *Cloning and biochemical characterization of plant methionine synthases and serine hydroxymethyltransferases* Roje, S 850

**Primary Reviewer:** L. Thomashow **Secondary Reviewer:** L. McConnell

Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 9:0.

B. Renewals

None

**4. BSL-2 MUA's**

A. New Protocols/Modifications

None

B. Renewals

None

**5. BSL-3 MUA's**

A. New Protocols/Modifications

None

B. Renewals

None

**6. Protocols approved in the interim**

None

**7. Pending MUAs**

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
As of 1/26/03, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue.
- B) *National Animal Disease Diagnostic Network* McElwain, T. 824  
Facility renovation completed March 2004. EH&S inspected the facility March 16 and 23, 2004. EH&S submitted the inspection checklist to the Chair of the IBC. Approval letter to be sent to the PI.
- C) *Biology of ruminant gammaherpesviruses associated with malignant catarrhal fever* Knowles, D. 823  
Facility renovation completed March 2004. EH&S inspected the facility March 16 and 23, 2004. EH&S submitted the inspection checklist to the Chair of the IBC. Approval letter to be sent to the PI.
- D) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
As of 1/26/2004, this MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56.
- E) *Id gene expression in prostate cancer* Chaudhary, J. 840  
As of 1/26/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab.

**8. Deferred MUA's**

- A) *Identification of mechanisms for differences in E. coli 0157:HF* Cobbold, R. 849

*prevalence among cattle on barley-and corn- based diets*

As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.

#### **9. Old Business**

- A) Discussion of MUA revision draft. The most recent version was distributed. Discussion of the concept that use of the new form should begin with the idea that it is a “living document” and can be revised by the IBC as comments are received. It was recommended that the new BSAF should be distributed via a memorandum from the Vice Provost for Research.

Motion to approve the revised MUA to be renamed the BSAF (Biological Safety Approval Form) made by L. Thomashow, 2<sup>nd</sup> by R. Bogden, passed 9:0.

#### **10. New Business**

None

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**April 26, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler (Chair), Dave Clark, Rob Corcoran, Mike Kluzik, Lorraine McConnell, Steven Russell, Linda Thomashow, Dan Nordquist, Hanu Pappu, [REDACTED]

**ABSENT:** Robert Bogden, Daniel Bradway, Keith Stormo

1. **MINUTES** – March 29, 2004  
Motion to approve by S. Russell 2<sup>nd</sup> by D. Clark, passed 6:0.

2. **ANNOUNCEMENTS**  
None.

**3. BSL-1 MUA's**

A. New Protocols/Modifications

- 1) *Mechanisms of downregulation of equine infectious anemia virus replication in activated macrophages* Oaks, J. 851  
**Primary Reviewer:** Bradway **Secondary Reviewer:** Clark

Motion to approve by D. Clark, 2<sup>nd</sup> by T. Baszler, passed 7:0.

- 2) *Specificity in Monomeric Ubiquitin Recognition* Alam, S. 852  
**Primary Reviewer:** Thomashow **Secondary Reviewer:** Pappu

The committee decided that before a vote can be made, the PI needs to submit an abstract of his project to be electronically routed to the IBC members for a vote. The IBC Coordinator will contact the PI to request this information.

B. Renewals  
None

**4. BSL-2 MUA's**

A. New Protocols/Modifications  
None

B. Renewals  
None

**5. BSL-3 MUA's**

A. New Protocols/Modifications  
None

B. Renewals



None

#### **6. Protocols approved in the interim**

None

#### **7. Pending MUAs**

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
Original Date Submitted: 9/19/03

On 1/26/04, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue. The IBC coordinator called the PI on 4/5/04 and requested that she write a letter to the IBC requesting a variance to work in the room with a biosafety cabinet.

- B) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
Original Date Submitted: 10/10/02

This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56. The IBC coordinator contacted the PI on 3/23/04 to make sure that the MUA we have on file is current. The PI confirmed that the MUA is current and he stated he would like to keep the MUA on our agenda since the project is set to begin the fall of 2004.

- C) *Id gene expression in prostate cancer* Chaudhary, J. 840  
Original Date Submitted: 12/11/03

As of 1/26/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab.

#### **8. Deferred MUA's**

- A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets* Cobbold, R. 849  
Original Date Submitted: 3/19/04

As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.

#### **9. Old Business**

- A) Dave Clark reported that the draft of the new BSAF form is still in process. He is waiting on comments from faculty on the form. Dave stated that the final draft should be sent to Jim Petersen in a month.

#### **10. New Business**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**May 24, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Mike Kluzik, Steve Russell, Lorraine McConnell, Dave Clark, Tim Baszler, Dan Nordquist, Dan Bradway, Hanu Pappu, Robert Corcoran, [REDACTED], Linda Thomashow, Robert Bogden

**ABSENT:** None

1. **MINUTES** – April 26, 2004  
Motion to approve by D. Clark 2<sup>nd</sup> by S. Russell, passed 6:0.

**2. ANNOUNCEMENTS**

A) Tim Baszler announced that he will be stepping down as chair of the IBC in August.

**3. BSL-1 MUA's**

**A. New Protocols/Modifications**

- 1) *Modulation of equine infectious anemia virus replication in macrophages in vivo* Oaks, J. 853

**Primary Reviewer:** Baszler

**Secondary Reviewer:** Bradway

Motion to approve by T. Baszler, 2<sup>nd</sup> by D. Bradway, passed 9:0.

- 2) *Evaluation of wheat and barley expressing candidate antifungal proteins for enhanced tolerance to root pathogens* Okubara, P. 855

**Primary Reviewer:** Pappu

**Secondary Reviewer:** Thomashow

Motion to approve by L. Thomashow, 2<sup>nd</sup> by D. Nordquist, passed 10:0.

- 3) *Molecular Regulation of Skeletal Muscle Growth and Development* Rodgers, B. 856

**Primary Reviewer:** Baszler

**Secondary Reviewer:** Bogden

Tim Baszler spoke with the PI and it was decided that the items listed under Section 2 part "c" of the MUA should have been under part "d". This change will be noted on the MUA.

Motion to approve by T. Baszler, 2<sup>nd</sup> by R. Bogden, passed 10:0.

- 4) *Pathogenesis + diagnostic testing of sheep naturally infected with OPPV* Herrmann, L. 857

**Primary Reviewer:** Bradway

**Secondary Reviewer:** Russell

Motion to approve by R. Bogden, 2<sup>nd</sup> by D. Bradway, passed 10:0.

- 5) *The Role of Alternate Hosts in the Epidemiology of Ascochyta Blight of Chickpea in the US PNW* Peever, T. 858

Primary Reviewer: Thomashow

Secondary Reviewer: Pappu

It was discussed that the PI needs to provide more information to the IBC regarding the containment, disposal and security of the plants being used in this protocol.

Motion to approve pending re-review by the primary and secondary reviewers of the additional information requested above by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 10:0.

B. Renewals

None

**4. BSL-2 MUA's**

A. New Protocols/Modifications

- 1) *Investigation of relationship between insulin resistance and duration of postpartum amenorrhea in healthy lactating women* McGuire, S. 854

Primary Reviewer: Clark

Secondary Reviewer: McConnell

Motion to approve by D. Clark, 2<sup>nd</sup> by M. Kluzik, passed 10:0.

B. Renewals

None

**5. BSL-3 MUA's**

A. New Protocols/Modifications

None

B. Renewals

None

**6. Protocols approved in the interim**

None

**7. Pending MUAs**

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
Original Date Submitted: 9/19/03

On 1/26/04, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue. The IBC coordinator called the PI on 4/5/04 and requested that she write a letter to the IBC requesting a variance to work in the room with a biosafety cabinet.

- B) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
Original Date Submitted: 10/10/02

This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56. The IBC coordinator contacted the PI on 3/23/04 to make sure that the MUA we have on file is current. The PI confirmed that the MUA is current and he stated he would like to keep the MUA on our agenda since the project is set to begin the fall of 2004.

- C) *Id gene expression in prostate cancer*  
Original Date Submitted: 12/11/03

Chaudhary, J. 840

As of 1/26/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab.

#### **8. Deferred MUA's**

- A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets*  
Original Date Submitted: 3/19/04

Cobbold, R. 849

As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.

#### **9. Old Business**

A) Dave Clark reported that the draft of the new BAF form will go out via a memo from Jim Petersen and Tim Baszler. The form will be able to be revised with future input. The old MUA form will be accepted until 12/31/04. After this date the IBC will return applications filled out on the old form and require that the new form be used. The memo will go out as early as next week.

#### **10. New Business**

**10. Meeting adjourned at 2:10pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**June 28, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Mike Kluzik, Steve Russell, Dave Clark, Tim Baszler, Dan Bradway, Hanu Pappu, [REDACTED], Linda Thomashow

**ABSENT:** Lorraine McConnell, Robert Corcoran, , Robert Bogden

**1. MINUTES – May 24, 2004**

Motion to approve by D. Bradway 2<sup>nd</sup> by S. Russell, passed 7:0.

**2. ANNOUNCEMENTS**

**3. BSL-1 MUA's**

**A. New Protocols/Modifications**

1) *Taxonomy, Identification of Plant Pathogens/ Ecology and Control of Plant Diseases* Dugan, F 863

**Primary Reviewer:** L. Thomashow

**Secondary Reviewer:** H. Pappu

Motion to approve pending receipt of documentation of the APHIS approval along with a modified IBC approval letter explaining that the committee is approving him to use organisms in his lab that are either indigenous to Washington State, or are obtained under USDA-APHIS PPW permit by L. Thomashow, 2<sup>nd</sup> by T. Baszler, passed 8:0.

2) *Identification of genetic factors conferring cold tolerance in winter wheat* Campbell, K. 861

**Primary Reviewer:** H. Pappu

**Secondary Reviewer:** L. Thomashow

Dave Clark stated that he corresponded with the PI regarding a note that was written on the MUA form. The PI stated that the form was filled out completely and they were just referencing a previous MUA (#805), but that this MUA is complete and does not need any additional information added to the form.

Motion to approve by D. Bradway, 2<sup>nd</sup> by L. Thomashow, passed 8:0.

3) *Functional/genomic analysis of vegetative storage protein proteolysis in leaf paraveinal mesophyll cells* Grimes, H. 860

**Primary Reviewer:** L. Thomashow

**Secondary Reviewer:** H. Pappu

Motion to approve by S. Russell, 2<sup>nd</sup> by L. Thomashow, passed 8:0.

4) *Anaplasma marginale genes involved in tick transmission* Dark, M. 859

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** S. Russell

Motion to approve by D. Bradway, 2<sup>nd</sup> by M. Kluzik, passed 8:0.

**B. Renewals**

None

#### 4. BSL-2 MUA's

##### A. New Protocols/Modifications

- 1) *Identification of Accessory Genes Requires for Prion Accumulation* Baszler, T. 865

Primary Reviewer: D. Bradway

Secondary Reviewer: R. Bogden

Motion to approve by D. Bradway, 2<sup>nd</sup> by M. Kluzik, passed 7:1. Tim Baszler abstained from voting.

- 2) *Igengae Yoga as Intervention to Enhance Immune Functioning* Blank, S. 864

Primary Reviewer: M. Kluzik

Secondary Reviewer: L. McConnell

Motion to approve by M. Kluzik, 2<sup>nd</sup> by T. Baszler, passed 8:0.

- 3) *Identifying Genes of Accessory Proteins Required for Prion Accumulation* Baszler, T. 862

Primary Reviewer: D. Bradway

Secondary Reviewer: R. Bogden

Motion to approve by D. Bradway, 2<sup>nd</sup> by M. Kluzik, passed 7:1. Tim Baszler abstained from voting.

##### B. Renewals

None

#### 5. BSL-3 MUA's

##### A. New Protocols/Modifications

None

##### B. Renewals

None

#### 6. Protocols approved in the interim

None

#### 7. Pending MUAs

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
Original Date Submitted: 9/19/03

On 1/26/04, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue. The IBC coordinator called the PI on 4/5/04 and requested that she write a letter to the IBC requesting a variance to work in the room with a biosafety cabinet.

- B) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
Original Date Submitted: 10/10/02

This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56. The IBC coordinator contacted the PI on 3/23/04 to make sure that the MUA we have on file is current. The PI confirmed that the MUA is current and he stated he would like to keep the MUA on our agenda since the project is set to begin the fall of 2004.

On 6/23/04 Mike Kluzik contacted the PI and requested that he transfer the information from his MUA to the new BAF form. The PI agreed to do this and will submit the BAF to the committee for review.

- C) *Id gene expression in prostate cancer*  
Original Date Submitted: 12/11/03

Chaudhary, J. 840

As of 1/26/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab.

## 8. Deferred MUA's

- A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets*  
Original Date Submitted: 3/19/04

Cobbold, R. 849

As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.

## 9. Old Business

## 10. New Business

A. Dave Clark mentioned that the second phase of the transgenic plant survey is being worked on. He mentioned that he will speak with Hanu Pappu and Linda Thomashow to get their feedback regarding the process of signing APHIS permits.

B. Dave Clark stated that he is working on a handbook for the IBC committee and he will forward a draft to the members for comments.

C. The committee discussed ideas for new members to be on the IBC. It was stated that Lynn Hermann has agreed to be on the committee beginning in August of 2004

D. It was discussed that the BMBL will be revised to include a chapter on bio-security because OBA will create a bio-security committee.

## 11. Meeting adjourned at 2:10pm

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**July 26, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Tim Baszler, Mike Kluzik, Lorraine McConnell, Dan Bradway, Steve Russell, Hanu Pappu, [REDACTED]

**ABSENT:** Linda Thomashow, Dave Clark, Rob Corcoran, Robert Bogden

**GUESTS:** Sandra Ristow

**1. MINUTES – June 28, 2004**

Motion to approve by S. Russell 2<sup>nd</sup> by M. Kluzik, passed 6:0.

**2. ANNOUNCEMENTS**

A. Tim Baszler introduced Sandra Ristow to the committee. Sandra will be the new chair of the IBC as of August.

**3. BSL-1 BAF's**

**A. New Protocols/Modifications**

1) *Genetically enhance wheat for quality, productivity and resistance to biotic and abiotic stresses* Steber, C. 872

**Primary Reviewer:** H. Pappu

**Secondary Reviewer:** L. Thomashow

Motion to approve by H. Pappu, 2<sup>nd</sup> by S. Russell, passed 6:0.

2) *In vitro pharmacodynamic activity of tigecycline, and investigational glycylcycline* Garrison, M. 869

**Primary Reviewer:** T. Baszler

**Secondary Reviewer:** M. Kluzik

Mike Kluzik has been corresponding with the PI regarding the facility being used. The facility is not currently approved at a BSL-2 level. NIH considers the organisms that the PI is working with to be at a BSL-2 level & the CDC guidelines do not list them. The committee would like the PI to resubmit the BAF specifying that he is using BSL-2 level organisms. The facility being used will need to be approved at a BSL-2 level.

Motion to deny protocol as a BSL-1 by T. Baszler, 2<sup>nd</sup> by M. Kluzik, passed 7/0.

3) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868

**Primary Reviewer:** L. Thomashow

**Secondary Reviewer:** H. Pappu

The PI was contacted by the IBC coordinator on July 19<sup>th</sup> and asked to submit an abstract for review with his application form. As of the meeting time the PI had not sent in an approval. The committee would like to see this before granting approval. The committee members wanted to know what the origin of the agent would be since he is getting a permit. The IBC coordinator will contact the PI to obtain this information.



Motion to defer until the materials requested are received.

B. Renewals

None

**4. BSL-2 BAF's**

A. New Protocols/Modifications

- 1) *Pathogenesis, transmission, and diagnosis of North American ruminant transmissible spongiform encephalopathies (NARTSEs) (excluding bovine spongiform encephalopathy or BSE)* Knowles, D. 871

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** S. Russell

Mike Kluzik reported that the room ADBF 3085 needs to be inspected.

Motion to approve pending EH&S approval of ADBF 3085, by D. Bradway, 2<sup>nd</sup> by T. Baszler, pass 7/0.

- 2) *Prion protein expression in enteric neurons and enteroglia of naturally infected sheep* Schneider, D. 870

**Primary Reviewer:** T. Baszler

**Secondary Reviewer:** R. Bogden

The application form mentions that animals are being used, but there are no facilities mentioned for housing the animals. The IBC coordinator will contact the PI to obtain this information.

Motion to approve by T. Baszler, 2<sup>nd</sup> by D. Bradway, passed 7/0.

- 3) *A novel approach to identify the virulence proteins secreted by Campylobacter jejuni* Konkell, M. 867

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** L. McConnell

The committee discussed that the protocol did not include a complete outline of what the PI is going to be doing. The committee would like to know what he will be doing with the animals, what type of e-coli will he be using, what the hosts for the bacteria are, and what genes he is interesting from. Mike Kluzik reported that the facilities are still under renovation. The PI stated that he will be using animals in this research, but did not list an ASAF number. The IBC coordinator will let the PI know that he will need to have ASAF approval prior to using animals in this research.

Motion to defer pending receipt of a complete outline of what the PI will be doing (as mentioned above) & pending approval of the facilities by EH&S by D. Bradway, 2<sup>nd</sup> by L. McConnell, passed 7/0.

- 4) *Transcriptional signatures of epidemic L. monocytogenes* Call, D. 866

**Primary Reviewer:** R. Bogden

**Secondary Reviewer:** M. Kluzik

Motion to approve by M. Kluzik, 2<sup>nd</sup> by D. Bradway, passed 7/0.

B. Renewals

None

## 5. BSL-3 BAF's

### A. New Protocols/Modifications

None

### B. Renewals

None

## 6. Protocols approved in the interim

None

## 7. Pending BAF's

- A) *Lysophosphatic Acid in Overian Cancer* Meier, K. 828  
Original Date Submitted: 9/19/03

On 1/26/04, EH&S reported that the lab is currently under positive pressure and it should be negative. The PI is working with the control shop regarding the pressure issue. The IBC coordinator called the PI on 4/5/04 and requested that she write a letter to the IBC requesting a variance to work in the room with a biosafety cabinet. The IBC coordinator called the PI on 7/20/04 and left a message to find out the status of her protocol.

- B) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
Original Date Submitted: 10/10/02

This MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56. The IBC coordinator contacted the PI on 3/23/04 to make sure that the MUA we have on file is current. The PI confirmed that the MUA is current and he stated he would like to keep the MUA on our agenda since the project is set to begin the fall of 2004.

On 6/23/04 Mike Kluzik contacted the PI and requested that he transfer the information from his MUA to the new BAF form. The PI agreed to do this and will submit the BAF to the committee for review.

- C) *Id gene expression in prostate cancer* Chaudhary, J. 840  
Original Date Submitted: 12/11/03

As of 1/26/2004 this MUA is pending EH&S review of the blood borne pathogen plan, biosafety manual and lab. The IBC coordinator called the PI on 7/20/04 and left a message to find out the status of the protocol.

## 8. Deferred BAF's

- A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets* Cobbold, R. 849  
Original Date Submitted: 3/19/04

As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety

manual. The IBC coordinator called the PI on 7/20/04 and left a message to find out the status of the protocol.

**9. Old Business**

**10. New Business**

A. The committee discussed how long a BAF should be in the pending status. The committee decided and voted (passed 7/0) that after a BAF has been on the pending list for six months, the PI will need to resubmit a new BAF for review.

**11. Meeting adjourned at 1:55pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**September 20, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Sandra Ristow, Scott Neils, Lynn Herrmann, Daniel Bradway, Steven Russell, Hanu Pappu, John Dahl, [REDACTED], Robert Bogden, Rob Corcoran, Mike Kluzik, Dave Clark

**ABSENT:** Linda Thomashow, Lorraine McConnell

Meeting called to order at 1:10pm

1. **MINUTES** – August 30, 2004  
Motion to approve by S. Neils 2<sup>nd</sup> by S. Russell, passed 8:0.

**2. ANNOUNCEMENTS**

- A. Dave Clark announced that we have found someone to fill the temporary position to assist with the Research Compliance Office until the end of January. This person, Malathi Jandhyala, will begin October 1<sup>st</sup>.

**3. BSL-1 BAF's**

A. New Protocols/Modifications

- 1) *Induction of Cytotoxic T Lymphocytes in Horses* Mealey, R. 876  
**Primary Reviewer:** S. Russell      **Secondary Reviewer:** D. Bradway

Motion to approve by S. Russell, 2<sup>nd</sup> by S. Neils, passed 9:0.

- 2) *Analysis of a mutant of Mycobacterium smegmatis which displays motility* Dahl, J. 878  
**Primary Reviewer:** R. Bogden      **Secondary Reviewer:** H. Pappu

**Discussion:** The committee discussed that mycobacterium smegmatis might be a BSL-2 instead of BSL-1. The BSL needs to be clarified. Lynn Herrmann offered to contact the CDC to find out which level it should be under, and John Dahl offered to contact the University of Arizona whom he has worked with before to get their advice on this issue. It was discussed that if the biosafety level is a 2, the researcher will need to have a BSL-2 level facility approved for this project.

Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility by D. Bradway, 2<sup>nd</sup> by L. Herrmann, passed 8:0. John Dahl abstained from voting.

B. Renewals

- 1) *EIAV Control by High Avidity Rev-Specific CTL Clones* Mealey, R. 559  
**Primary Reviewer:** L. Herrmann      **Secondary Reviewer:** S. Russell

Motion to approve by S. Neils, 2<sup>nd</sup> by D. Bradway, passed 9:0.

**4. BSL-2 BAF's**

**A. New Protocols/Modifications**

1) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Shelden, E. 877

**Primary Reviewer:** J. Dahl

**Secondary Reviewer:** S. Neils

**Discussion:** The committee discussed that the PI should have marked “yes” on page 3 of the BAF that he is using human blood, bodily fluids, or tissues. The PI also needs to fill out section 5 relating to using human blood, bodily fluids, or tissues. The committee also discussed that the PI should have a separate Bloodborne Pathogens Plan or should revise the existing biosafety manual to include this plan (committee noted BMBL Appendix H, page 234).

Motion to approve pending submittal section 5 of the BAF, and that the PI submit a separate Bloodborne Pathogens Plan or should revise the existing biosafety manual to include this plan due to the fact he is working with human cells by J. Dahl, 2<sup>nd</sup> by S. Neils, passed 9:0.

**B. Renewals**

None

**5. BSL-3 BAF's**

**A. New Protocols/Modifications**

1) *Analysis of the stringent response on Mycobacterium tuberculosis virulence* Dahl, J. 879

**Primary Reviewer:** R. Bogden

**Secondary Reviewer:** H. Pappu

**Discussion:** The committee discussed that the PI needs to correctly list the rooms according to the BSL on page 3 of the BAF. It was mentioned that EH&S would like to hold an open house in the BSL-3 lab prior to the research starting in the lab. On page 5, section 4 needs to clarify which hosts are which BSL. The committee also requested that the PI clarify the shipping and receiving procedures of the m. tuberculosis.

Motion to defer by J. Murphy, 2<sup>nd</sup> by R. Bogden, passed 8:0. John Dahl was not present during the discussion and abstained from voting.

2) *Generating a strain of Mycobacterium bovis for eventual analysis using a cattle infection model* Dahl, J. 880

**Primary Reviewer:** R. Bogden

**Secondary Reviewer:** H. Pappu

Motion to approve pending final approval of the facilities & manual by EH&S by S. Neils, 2<sup>nd</sup> by L. Herrmann, passed 7:0. John Dahl was not present during the discussion and abstained from voting. D. Bradway was not present during the vote.

**B. Renewals**

1) *Processing of complex sounds in the auditory system of bats* Portfors, C. 748

**Primary Reviewer:** S. Russell

**Secondary Reviewer:** D. Bradway

Motion to approve by S. Neils, 2<sup>nd</sup> by S. Russell, passed 8:0.

**6. Protocols approved in the interim**

None

## 7. Pending BAF's

None

## 8. Deferred BAF's

A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets* Cobbold, R. 849  
Originally Reviewed: 3/29/04

- As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.
- 8/23/04: Mike Kluzik reported that he is still working with the PI on this

B) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868  
Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.

C) *A novel approach to identify the virulence proteins secreted by Campylobacter jejuni* Konkel, M. 867  
Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- The PI submitted a copy of the project abstract on 8/3/04.
- Committee will re-review his application with a copy of the abstract during the 9/20/04 meeting.

Motion to approve pending final approval of the lab by EH&S by R. Bogden, 2<sup>nd</sup> by S. Neils, passed 8:0.

## 9. Old Business

- A. Dave Clark presented the revised IBC Handbook and asked the committee to review it and make notes regarding topics that came up during the meeting.

## 10. New Business

## 11. Meeting adjourned at 2:58pm

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**August 30, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Sandra Ristow, Scott Neils, Lynn Herrmann, Daniel Bradway, Steven Russell, Hanu Pappu, John Dahl, [REDACTED], Robert Bogden, Rob Corcoran, Mike Kluzik, Dave Clark

**ABSENT:** Linda Thomashow, Lorraine McConnell

**GUESTS:** Tim Baszler

Meeting called to order at 1:10pm

1. **MINUTES** – July 26, 2004  
Motion to approve by H. Pappu 2<sup>nd</sup> by L. Herrmann, passed 8:0.

**2. ANNOUNCEMENTS**

- A. All members introduced themselves to the committee
- B. Dave Clark announced that [REDACTED], the IBC Coordinator will be going on maternity leave sometime early in November. The Research Compliance Office is working on hiring part time help as per the memo sent by Jim Petersen to the chairs of the compliance committees.

**3. BSL-1 BAF's**

**A. New Protocols/Modifications**

- 1) *Regulation and Function of Small Heat Shock Proteins in Cultured Cells* Shelden, E. 873

**Primary Reviewer:** S. Russell                      **Secondary Reviewer:** M. Kluzik

Motion to approve by S. Russell, 2<sup>nd</sup> by M. Kluzik, passed 9:0.

**B. Renewals**

- 1) *An integrated physical and expression map of barley for Triticaceae improvement* Kleinhofs, A. 742

**Primary Reviewer:** L. Thomashow                      **Secondary Reviewer:** H. Pappu

Motion to approve by H. Pappu, 2<sup>nd</sup> by L. Herrmann, passed 9:0.

- 2) *Aquaculture WA subproject: Genetic control of IHNV resistance in rainbow trout* Thorgaard, G. 827

**Primary Reviewer:** S. Russell                      **Secondary Reviewer:** D. Bradway

Motion to approve by R. Bogden, 2<sup>nd</sup> by D. Bradway, passed 9:0.

**4. BSL-2 BAF's**

**A. New Protocols/Modifications**

- 1) *The characterization of tick stage-specific genes of Babesia bovis* . Lau, A. 875  
Primary Reviewer: L. Herrmann Secondary Reviewer: L. McConnell

Motion to approve by D. Bradway, 2<sup>nd</sup> by S. Russell, passed 9:0.

**B. Renewals**

- 1) *Ecology and Epidemiology of Listeria monocytogenes* Borucki, M. 722  
Primary Reviewer: R. Bogden Secondary Reviewer: S. Ristow

The committee requested that M. Borucki verify that the animals being used are incinerated after they are autoclaved.

Motion to approve pending verification that the animals being used are incinerated after they are autoclaved by D. Bradway, 2<sup>nd</sup> by L. Herrmann, passed 9:0.

**5. BSL-3 BAF's**

**A. New Protocols/Modifications**

- 1) *Recombination potential of West Nile virus and St. Louis Encephalitis virus in mosquito cells* Borucki, M. 874  
Primary Reviewer: D. Bradway Secondary Reviewer: L. Herrmann

The committee discussed that the researcher did not attach an abstract to the protocol paperwork, and would like this to be submitted and added to the file.

Motion to approve pending receipt of the abstract for the file by S. Neils, 2<sup>nd</sup> by J. Dahl, passed 9:0.

**B. Renewals**

None

**6. Protocols approved in the interim**

None

**7. Pending MUAs**

- A) *CAREER: Analysis of the Stringent Response in Mycobacterium Tuberculosis* Dahl, J. 788  
Originally Reviewed: 10/2002

- As of 1/26/2004, this MUA is still in progress. Funding has been obtained and the project is set to begin in July or August of 2004 after the remodel of Eastlick B56.
- On 3/23/04 the IBC Coordinator checked with the PI to make sure that the MUA form is correct and that there were no changes or updates that needed to be made to it.
- 7/23/04: Mike Kluzik contacted PI by email & requested that he fill out the new BAF form
- 8/30/04: The PI will be submitting his the new BAF form for the committee to review

**8. Deferred MUA's**



A) *Identification of mechanisms for differences in E. coli 0157:HF prevalence among cattle on barley-and corn- based diets* Cobbold, R. 849  
Originally Reviewed: 3/29/04

- As of 3/23/2004, EH&S is working with the PI regarding facilities to be used, and the biosafety manual.
- 8/23/04: Mike Kluzik reported that he is still working with the PI on this

B) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868  
Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.

C) *A novel approach to identify the virulence proteins secreted by Campylobacter jejuni* Konkel, M. 867  
Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- The PI submitted a copy of the project abstract on 8/3/04.
- 8/30/04: The committee requested that the IBC Coordinator check to see which type of e-coli he will be using.

## 9. Old Business

## 10. New Business

A. IBC Handbook – Dave Clark introduced the draft IBC Handbook to the committee. He asked that comments and suggestions be submitted to him within two weeks. He would like to get the revised draft back to the committee for the September IBC meeting.

B. OGRD Memo #13 - Dave Clark introduced the draft OGRD Memo #13 to the committee. He asked that comments and suggestions be submitted to him within two weeks. He would like to get the revised draft back to the committee for the September IBC meeting.

## 11. Meeting adjourned at 2:31pm

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**October 25, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Sandra Ristow, Mike Kluzik, John Dahl, Steven Russell, Scott Neils, [REDACTED],  
Dave Clark, Rob Corcoran, Robert Bogden, Daniel Bradway, Linda Thomashow,

**ABSENT:** Lynn Herrmann, Hanu Pappu

Meeting called to order at 1:10pm

**1. MINUTES – September 20, 2004**

Motion to approve by S. Neils 2<sup>nd</sup> by R. Bogden, passed 6:0

**2. ANNOUNCEMENTS**

- A. Malathi Jandhyala will be assisting with Research Compliance office while [REDACTED] is on maternity leave. Any mail regarding IBC will be forwarded to Malathi Jandhyala.
- B. Dave Clark gave a synopsis of a bio safety conference he attended during the past week.
- C. There was an open house for John Dahl's BSL-3 Lab.
- D. Dave Clark informed about the status of biosafety officer search. Two potential candidates were interviewed and the search committee will meet on October 29<sup>th</sup> to discuss the candidates.

**3. BSL-1 BAF's**

**A. New Protocols/Modifications**

- 1) *Plant Metabolic Engineering* Lange, M. 883  
**Primary Reviewer:** L. Thomashow **Secondary Reviewer:** S. Neils

Motion to approve pending submittal of the abstract, and review of the abstract by the chair of IBC and primary reviewer by L.Thomashow, 2<sup>nd</sup> by S.Neils, passed 8:0

**4. BSL-2 BAF's**

**A. New Protocols/Modifications**

- 1) *Role of phenazines in pathogenicity of Pseudomonas Aeruginosa in lung infection models* Thomashow, L. 881  
**Primary Reviewer:** S. Ristow **Secondary Reviewer:** D. Bradway

Motion to approve by D. Bradway, 2<sup>nd</sup> by R. Bogden, passed 7:0. Linda abstained from voting.

- 2) *Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer* Schulze-Makuch, D. 882  
**Primary Reviewer:** J. Dahl **Secondary Reviewer:** S. Ristow

**Discussion:** The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria.

Motion to defer until the completion of biosafety manual and revision of BAF by S. Neils, 2<sup>nd</sup> by J.Dahl, passed 8:0

3) *The role of super-shedders in determining feedlot pen* Cobbold, R. 884  
*Prevalence of E.Coli O157:H7.*

**Primary Reviewer:** S. Russell      **Secondary Reviewer:** R. Bogden

Motion to approve by S. Russell, 2<sup>nd</sup> by D. Bradway, passed 8:0

4) *Host cellular pathways activated by Trichinella Spiralis* Jasmer, D.L. 381

**Primary Reviewer:** D. Bradway      **Secondary Reviewer:** S. Russell

Motion to approve by R.Bogden, 2<sup>nd</sup> by D. Bradway, passed 8:0

5) *Scatter factor induced carcinoma cell migration, Pem* Lindsey, J.S. 885  
*Homeobox Gene Function During Spermatogenesis, Mig-7: Cancer cell-specific target and marker potential*

**Primary Reviewer:** S. Russell      **Secondary Reviewer:** S. Ristow

**Discussion:** The committee discussed that the lab ventilation should be in place to process the BAF for approval.

Motion to approve pending the EH&S approval of the lab by S.Russell, 2<sup>nd</sup> by L.Thomshow, passed 7:0

#### **5. BSL-3 BAF's**

None

#### **6. Protocols approved in the interim**

None

#### **7. Pending BAF's**

A) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing biosafety manual to include this plan due to the fact that he is working with human cells.
- 10/25/04: EH &S is meeting with the PI to discuss BAF.

B) *Analysis of a mutant of Mycobacterium smegmatis which displays motility* Dahl, J. 878

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility

C) *Generating a strain of Mycobacterium bovis for eventual analysis using a cattle infection model* Dahl, J. 880  
Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending final approval of the facilities & manual by EH&S

## 8. Deferred BAF's

A) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868  
Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.

B) *Analysis of the stringent response on Mycobacterium tuberculosis virulence* Dahl, J. 879  
Originally Reviewed: 9/22/04

- 9/22/04: The IBC decided to defer this protocol until the next meeting. The PI needs to submit revised pages of BAF and the answer to the shipping and receiving procedures.

## 9. Old Business

A. Dave Clark informed the committee that he is working on the revisions of IBC manual

## 10. New Business

A. The committee decided to form a sub committee to discuss Mycobacterium Smegmatis. Dave Clark and Sandra Ristow will look into this issue and report back to the committee.

Meeting was adjourned at 2:50 pm.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**November 29, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**Due to lack of quorum, this was not an official IBC meeting. The notes below reflect a discussion of the members present.**

**PRESENT:** Sandra Ristow, Mike Kluzik, Steven Russell, Rob Corcoran, Linda Thomashow, Lynn Herrmann, Hanu Pappu, Malathi Jandhyala

**ABSENT:** [REDACTED], Dave Clark, Robert Bogden, Daniel Bradway, Scott Neils, John Dahl

**1. MINUTES – October 25, 2004**

**2. ANNOUNCEMENTS**

A) Sandra Ristow will be out of town for December 13<sup>th</sup> IBC meeting. Hanu Pappu will be the interim chair for the December 13, 2004 meeting.

**3.BSL-1 BAF's**

None

**4. BSL-2 BAF's**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

A) 1) Plant *Metabolic Engineering*  
Originally Reviewed: 10/25/04

Lange, M. 883

- 10/25/04: Motion to approve pending submittal of the abstract, and review of the abstract by the chair of IBC and primary reviewer
- 11/29/04: Chair of IBC and primary reviewer reviewed the abstract and approved it.

**7. Pending BAF's**

A) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Sheldon, E. 877  
Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing bio-safety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.

B) *Analysis of a mutant of Mycobacterium smegmatis which displays motility* Dahl, J. 878

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility.
- 11/29/04: Mike Kluzik updated the status of the facility.

C) *Scatter factor induced carcinoma cell migration, Pem Homeobox Gene Function during Spermatogenesis, Mig-7: Cancer cell-specific target and marker potential* Lindsey, J.S. 885

Originally Reviewed: 10/25/04

- The committee discussed that the lab ventilation should be in place to process the BAF for approval. Motion to approve pending the EH&S approval of the lab.
- 11/29/04: Mike Kluzik updated the status of the flow hood in the lab.

## 8. Deferred BAF's

A) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.
- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.

B) *Analysis of the stringent response on Mycobacterium Tuberculosis virulence* Dahl, J. 879

Originally Reviewed: 9/22/04

- The IBC decided to defer this protocol until the next meeting. The PI needs to submit revised pages of BAF and the answer to the shipping and receiving procedures.
- 11/29/04: Mike Kluzik updated the status lab and bio safety manual. PI will try to have the lab and manual ready by December IBC meeting.

C) *Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer* Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria. Motion to defer until the completion of bio-safety manual and revision of BAF.
- 11/29/04: Mike Kluzik updated the status of the lab.

**9. Old Business**

**10. New Business**

- A) Rob Corcoran informed the committee regarding the possibility of having a BSL-3 lab in Puyallup. In July 2004, Rob Corcoran and Pete Jacoby were in a meeting in Puyallup discussing the possibility of having a BSL-3 lab for conducting experiments related to sudden oak death. They were considering the use of temporary portable BSL-3 lab (self-contained).
- B) Rob Corcoran also announced about a meeting that took place to upgrade Vet Med ARU building 199G to a BSL-3 facility.

**Meeting was adjourned at 1:30 pm.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**December 13, 2004**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Mike Kluzik, Daniel Bradway Steven Russell, Linda Thomashow, Lynn Herrmann, Hanu Pappu, Scott Neils, Malathi Jandhyala, and Keith Stormo.

**ABSENT:** [REDACTED], Robert Bogden, John Dahl, and Sandra Ristow, Rob Corcoran,

**1. MINUTES – October 25, 2004**

Motion to approve by S.Russell and 2<sup>nd</sup> by L. Thomashow, passed 7:0

**2. ANNOUNCEMENTS**

A) New Committee member, Jennifer Hogan from Spokane will be included in the IBC roster from January onwards. Jennifer Hogan was contacted about the Curriculum Vitae. President's office was notified to include the new committee member on the roster from January onwards.

**3.BSL-1 BAF's**

**A. New Protocols/Modifications**

None

**B. Renewals**

1) *Nematode intestinal antigens that induce local Th2  
Lymphocytes and immunity*

Jasmer D.P. 712

**Primary Reviewer:** S. Russell

**Secondary Reviewer:** L. Herrmann

The committee discussed that the application is not complete until the part II and section III are filled. L. Herrmann will contact the PI and review the application.

Motion to approve pending submittal of application by completing the part II and section III (LARC number) and re review by secondary reviewer by L. Hermann, 2<sup>nd</sup> by D. Clark, passed 7:0

**4. BSL-2 BAF's**

**A. New Protocols/Modifications**

1) *Analysis of the immune response to  
M. avium Subvsp.paratuberculosis*

Davis, W.C. 886

**Primary Reviewer:** J. Dahl

**Secondary Reviewer:** D. Broadway

The committee discussed that the researcher did not attach an abstract to the protocol paperwork, and would like this to be submitted and added to the file. Also, on the BAF form, section 4, question 7 was not marked. Malathi Jandhyala will contact the PI.

Motion to approve pending submittal of abstract and completing the section 4, question 7 by D. Broadway, 2<sup>nd</sup> by L. Herrman, passed 7:0

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

A) 1) *Plant Metabolic Engineering*  
Originally Reviewed: 10/25/04

Lange, M. 883



- 10/25/04: Motion to approve pending submittal of the abstract, and review of the abstract by the chair of IBC and primary reviewer
- 11/29/04: Chair of IBC and primary reviewer reviewed the abstract and approved it.

## 7. Pending BAF's

A) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing bio-safety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.
- 12/13/04: Mike Kluzik informed the committee that EH&S is waiting for the PI to submit the biosafety manual with condensed version of blood borne pathogen standard attached.

B) *Analysis of a mutant of Mycobacterium smegmatis which displays motility* Dahl, J. 878

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility.
- 11/29/04: Mike Kluzik updated the status of the facility.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting for biosafety manual to approve the lab.

C) *Scatter factor induced carcinoma cell migration, Pem Homeobox Gene Function during Spermatogenesis, Mig-7: Cancer cell-specific target and marker potential* Lindsey, J.S. 885

Originally Reviewed: 10/25/04

- The committee discussed that the lab ventilation should be in place to process the BAF for approval. Motion to approve pending the EH&S approval of the lab.
- 11/29/04: Mike Kluzik updated the status of the flow hood in the lab.
- 12/13/04: Mike Kluzik updated that as soon as the flow hood in the lab is certified the lab will be approved.

## 8. Deferred BAF's

A) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.

- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.
- 12/13/04: Need to hear from the PI about the abstract.

**B) *Analysis of the stringent response on Mycobacterium Tuberculosis virulence***

Dahl, J. 879

Originally Reviewed: 9/22/04

- The IBC decided to defer this protocol until the next meeting. The PI needs to submit revised pages of BAF and the answer to the shipping and receiving procedures.
- 11/29/04: Mike Kluzik updated the status lab and bio safety manual. PI will try to have the lab and manual ready by December IBC meeting.
- 12/13/04: Biosafety manual needs to be submitted for approval

**C) *Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer***

Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria. Motion to defer until the completion of biosafety manual and revision of BAF.
- 11/29/04: Mike Kluzik contacted the PI and communicated the concerns of the committee regarding the generation of aerosol. The PI agreed to purchase the bio safety cabinet and complete the bio safety manual. The cabinet needs to be installed and certified in order to approve the lab.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting to hear about the bio safety cabinet so that the lab can be approved.

## **9. Old Business**

A) Dave Clark updated the committee regarding the recruitment of bio safety officer. He informed the IBC that three candidates were interviewed and none of them met the requirements of the job description. The search committee decided that the job description needs to be refined before advertising again. The search committee also recommended the recruitment of interim biosafety officer to the vice provost of research.

B): Dave gave an update on IBC manual.

C) Dave informed the committee that on presidential committee website, the description of IBC role regarding informed carcinogens and mutagens needs to be corrected. IBC does not have any role regarding carcinogens and mutagens and should be removed. Motion to change the charter on the presidential committee IBC site about carcinogens and mutagens by D. Clark and 2<sup>nd</sup> by D. Broadway, passed 7:0

## **10. New Business**

A) Tentatively the next IBC meeting will be on January 31<sup>st</sup> 2005 from 1:10 to 2:30 pm. Since Jennifer Hogan from WSU Spokane agreed to be on the IBC committee, we will be using WHETS facility from January onwards.

**Meeting was adjourned at 2:20 pm.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**January 31, 2005**  
**1:10-2:30 pm**  
**WSU Pullman (MURW 52), WSU Spokane (SIRTI 317)**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Rob Corcoran, Linda Thomashow, Lynn Herrmann, Robert Bogden, John Dahl, Scott Neils, Malathi Jandhyala and Jennifer Hogan.

**GUESTS:** [REDACTED]

**ABSENT:** [REDACTED] Daniel Bradway, Steven Russell, and Hanu Pappu.

**1. MINUTES – December 13, 2004**

Motion to approve by L. Thomashow and 2<sup>nd</sup> by, L. Herrmann, passed 7:0

**2. ANNOUNCEMENTS**

A) Welcome Jennifer!

B) Sandra informed that they are looking for an alternate to Hanu Pappu for this semester. Hanu will continue to review the protocols and send in the comments.

**3. BSL-1 BAF's**

A. New Protocols/Modifications

1) *Identification of T-Cell Antigens for Q fever Vaccination* Brown, W. 887

**Primary Reviewer:** S. Russell **Secondary Reviewer:** J. Dahl

The committee discussed the need for some sort of documentation from the Texas A&M to show total inactivation of Coxiella Burnetti before shipping it to WSU. The committee requested the PI to provide clarification in this regard.

Motion to approve pending clarification of documentation from Texas A&M regarding inactivation of Coxiella Burnetti and re review by primary and secondary reviewers by J. Dahl, 2<sup>nd</sup> by S. Neils, passed 7:0

2) *Biogeochemical Cycling of Heavy Metals in Lake Coeur d'Alene Sediments: The Role of Indigenous Microbial Communities* Peyton, B. 888

**Primary Reviewer:** R. Bogden **Secondary Reviewer:** S. Neils

Motion to approve by J.Dahl and 2<sup>nd</sup> by L. Thomashow, passed 7:0

3) *Establishing Ordered Library Sets of Cereals-Associated Gaeumannomyces Species for Genome Sequencing and Resource Development* Okubara, P. 889

**Primary Reviewer:** L.Thomashow **Secondary Reviewer:** H. Pappu

Motion to approve by L. Thomashow and 2<sup>nd</sup> by J. Dahl, passed 7:0

4) *Regulation and Function of Small Heat Shock Proteins in Cultured Cells* Shelden, E. 873

**Primary Reviewer:** S. Russell **Secondary Reviewer:** M. Kluzik

Motion to approve by S. Neils and 2<sup>nd</sup> by J. Hogan, passed 7:0

**4. BSL-2 BAF's**

A. New Protocols/Modifications

1) *Investigation and Evaluation of Dairy Cattle Causing Pathogens* Fox, L. 890  
Primary Reviewer: D. Bradway Secondary Reviewer: S. Ristow  
Motion to approve by L. Thomashow and 2<sup>nd</sup> by R. Bogden, passed 7:0

#### 5. BSL-3 BAF's

None

#### 6. Protocols approved in the interim

A) *Analysis of the immune response to M. avium Subsp. paratuberculosis* Davis, W.C. 886

Originally Reviewed: 12/13/04

- The committee discussed that the researcher did not attach an abstract to the protocol paperwork, and would like this to be submitted and added to the file. Also, on the BAF form, section 4, question 7 was not marked. Malathi Jandhyala will contact the PI. Motion to approve pending submittal of abstract and completing the section 4, question 7.
- 01/21/05: The PI gave permission to Malathi Jandhyala mark question 7 under section 4 on the BAF form. PI has submitted the abstract.
- 01/24/05: Protocol approved.

#### 7. Pending BAF's

A) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing biosafety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.
- 12/13/04: Mike Kluzik informed the committee that EH&S is waiting for the PI to submit the biosafety manual with condensed version of blood borne pathogen standard attached.
- 1/31/05: Need to hear from PI

B) *Analysis of a mutant of Mycobacterium smegmatis which displays motility* Dahl, J. 878

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility.
- 11/29/04: Mike Kluzik updated the status of the facility.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting for biosafety manual to approve the lab.
- 1/31/05: The PI is still working on biosafety manual.

C) *Scatter factor induced carcinoma cell migration, Pem Homeobox Gene Function during Spermatogenesis, Mig-7: Cancer cell-specific target and marker potential* Lindsey, J.S. 885

Originally Reviewed: 10/25/04

- The committee discussed that the lab ventilation should be in place to process the BAF for approval. Motion to approve pending the EH&S approval of the lab.

- 11/29/04: Mike Kluzik updated the status of the flow hood in the lab. Waiting for the hood to be certified before giving approval for the protocol.
- 12/13/04: Mike Kluzik updated that as soon as the flow hood in the lab is certified the lab will be approved.
- 1/25/05: Lindsey called and informed that the flow hood in the lab has been certified.
- 1/31/05: Approved.

D) *Nematode intestinal antigens that induce local Th2  
Lymphocytes and immunity*

Jasmer, D.P. 712

Originally Reviewed: 12/13/04

- The committee discussed that the application is not complete until the part II and section III are filled. L. Herrmann will contact the PI and review the application. Motion to approve pending submittal of application by completing the part II and section III (LARC number) and re review by secondary reviewer.
- 01/21/05 Lynn has contacted the PI and the PI is still working on the suggestions.
- 1/31/05: Approved.

8. Deferred BAF's

A) *Characterization of Glucanase Inhibitor Proteins: A New  
Counter Defense Mechanism by Plant Pathogens*

Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.
- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.
- 12/13/04: Need to hear from the PI about the abstract.
- 1/31/05: Need to hear from the PI about the abstract.

B) *Analysis of the stringent response on Mycobacterium  
Tuberculosis virulence*

Dahl, J. 879

Originally Reviewed: 9/22/04

- The IBC decided to defer this protocol until the next meeting. The PI needs to submit revised pages of BAF and the answer to the shipping and receiving procedures.
- 11/29/04: Mike Kluzik updated the status lab and bio safety manual. PI will try to have the lab and manual ready by December IBC meeting.
- 12/13/04: Biosafety manual needs to be submitted for approval
- 1/31/05: The PI communicated that the manual will be ready in couple of weeks.

C) *Removal of Giardia Intestinales cysts from ground  
water using a surfactant modified zeolite barrier in a model  
aquifer*

Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would

numerate the bacteria. Motion to defer until the completion of biosafety manual and revision of BAF.

- 11/29/04: Mike Kluzik updated the status of the lab. As soon as the biosafety cabinet is ready, the protocol can be approved.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting to hear about the bio safety cabinet so that the lab can be approved.
- 1/31/05: The PI is waiting to buy the cabinet. This should be done by March.

#### **9. Old Business**

A. Chain-of-Custody: the procedures for receipt of biological materials will be addressed in the IBC Handbook which is under development.

#### **10. New Business**

##### **A) Change in BAF instruction form**

The BAF instructions will be revised regarding #5. The instructions will not indicate that an annual renewal is required. This will be formalized in the IBC Handbook which is under development.

##### **B) Proposed form to request for amendment to approved protocol**

Proposed form to request amendment to approved protocol: The Research Compliance Office will develop a draft BAF Amendment Form for the IBC to review and approve.

##### **C) SPPM policy for Bird and Bat Waste**

Mike Kluzik briefly discussed this policy. The Chair of the committee will respond to Procedures and Forms (and cc the Vice Provost for Research).

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**February 28, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Rob Corcoran, Linda Thomashow, Lynn Herrmann, Robert Bogden, John Dahl, Steven Russell, Daniel Bradway [REDACTED] and Malathi Jandhyala.

**GUESTS:** [REDACTED]

**ABSENT:** Scott Neils, Jennifer Hogan and Hanu Pappu.

**1. MINUTES – January 31, 2005**

Motion to approve by L. Herrmann and 2<sup>nd</sup> by, R. Bogden, passed 6:0

**2. ANNOUNCEMENTS**

A) IBC meeting venue has been shifted back to NEILL HALL from February 28, 2005.

**3. BSL-1 BAF's**

A. New Protocols/Modifications

1) *Epidemiology and molecular biology of virus Diseases of grapevine*

Rayapati, N.A. 891

**Primary Reviewer:** L. Thomashow

**Secondary Reviewer:** H. Pappu

The committee discussed that the abstract is not informative.

Motion to approve pending incorporating more details in methodology and re review by primary reviewer by L. Thomashow, 2<sup>nd</sup> by D. Bradway, passed 9:0

**4. BSL-2 BAF'**

A. New Protocols/Modifications

1) *Cell Mediated Immune Mechanisms of Cattle in Response to Babesia Infections*

Goff, W.L. 892

**Primary Reviewer:** J. Dahl

**Secondary Reviewer:** S. Russell

The committee discussed that BCG is listed in BMBL as hazardous to lab personnel and hence on section 3, page 4 of 11, human hazard should be marked. Also, on page 4 of 11, answer to question 5 in the box, need to add 'composting' after incineration. IBC Coordinator should call the PI and can do the changes administratively.

Motion to approve pending above suggested changes and reviewed by IBC Coordinator by D. Bradway and 2<sup>nd</sup> by J.Dahl, passed 9:0.

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

A) *Identification of T-Cell Antigens for Q fever Vaccination*  
Originally Reviewed 1/31/05

Brown, W. 887

- 1/31/05: Motion to approve pending clarification of documentation from Texas A&M regarding inactivation of Coxiella Burnetti
- 2/2/05: Approved with clarification from the PI

**B) *Analysis of a mutant of Mycobacterium smegmatis which displays motility***

Dahl, J. 878

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending the CDC stating mycobacterium smegmatis is a BSL-1 organism or if it is decided that it is a BSL-2, approval is pending EH&S approval of a BSL-2 facility.
- 11/29/04: Mike Kluzik updated the status of the facility.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting for biosafety manual to approve the lab.
- 2/16/05: Approved.

**C) *Analysis of the stringent response on Mycobacterium Tuberculosis virulence***

Dahl, J. 879

Originally Reviewed: 9/22/04

- The IBC decided to defer this protocol until the next meeting. The PI needs to submit revised pages of BAF and the answer to the shipping and receiving procedures.
- 11/29/04: Mike Kluzik updated the status lab and bio safety manual. PI will try to have the lab and manual ready by December IBC meeting.
- 12/13/04: Biosafety manual needs to be submitted for approval.
- 2/16/05: Approved.

**D) *Scatter factor induced carcinoma cell migration, Pem Homeobox Gene Function during Spermatogenesis, Mig-7: Cancer cell-specific target and marker potential***

Lindsey, J.S. 885

Originally Reviewed: 10/25/04

- The committee discussed that the lab ventilation should be in place to process the BAF for approval. Motion to approve pending the EH&S approval of the lab.
- 11/29/04: Mike Kluzik updated the status of the flow hood in the lab. Waiting for the hood to be certified before giving approval for the protocol.
- 12/13/04: Mike Kluzik updated that as soon as the flow hood in the lab is certified the lab will be approved.
- 1/25/05: Lindsey called and informed that the flow hood in the lab has been certified.
- 01/31/05: Approved

**7. Pending BAF's**

**A) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells***

Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing biosafety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.
- 12/13/04: Mike Kluzik informed the committee that EH&S is waiting for the PI to submit the biosafety manual with condensed version of blood borne pathogen standard attached.
- 1/31/05: Need to hear from PI
- 2/28/05: Need to hear from PI



## 8. Deferred BAF's

### A) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens*

Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.
- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.
- 12/13/04: Need to hear from the PI about the abstract.
- 1/31/05: Need to hear from the PI about the abstract.
- 2/28/05: Need to hear from the PI about the abstract.

### C) *Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer*

Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria. Motion to defer until the completion of biosafety manual and revision of BAF.
- 11/29/04: Mike Kluzik updated the status of the lab. As soon as the biosafety cabinet is ready, the protocol can be approved.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting to hear about the bio safety cabinet so that the lab can be approved.
- 1/31/05: The PI is waiting to buy the cabinet.
- 2/28/05: Need to hear from the PI.

## 9. Old Business

A) Amendment Form: Dave discussed the need of an amendment form for IBC protocols. He distributed the amendment form draft and requested input from the committee members.

## 10. New Business

None

Meeting was adjourned at 1:50 P.M.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**March 28, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Linda Thomashow, Lynn Herrmann, Scott Neils, Steven Russell, Daniel Bradway, Jennifer Hogan, [REDACTED] and Malathi Jandhyala.

**GUESTS:** [REDACTED]

**ABSENT:** John Dahl, Rob Corcoran, Robert Bogden and Hanu Pappu.

**1. MINUTES – February 28, 2005**

Motion to approve with corrections to the typos and including [REDACTED]'s name in the list of members present in the February meeting by L. Herrmann and 2<sup>nd</sup> by, L. Thomashow, passed 7:0

**2. ANNOUNCEMENTS**

None

**3. BSL-1 BAF's**

None

**4. BSL-2 BAF's**

**A. New Protocols/Modifications**

1) *Emergence of Zoonotic Food and Water-Borne MDR-Salmonella* Cobbold, R. 894

**Primary Reviewer: D. Bradway,**

**Secondary Reviewer: S. Russell**

**Discussion:** The IBC discussed the protocol and felt everything is fine. Mike explained the protocol with regards to meeting the blood borne pathogen standard. The researchers marked 'yes' to human blood or tissues because they will be obtaining samples from or of human feces. The OSHA/L&I Blood borne pathogen standard is required if there are visible signs of blood in the feces; the researchers are going to use feces without any visible signs of blood and hence, on page 5, they have marked 'no' to section 5, question 3.

Motion to approve by S. Russell, 2<sup>nd</sup> by S. Neils, passed 7:0

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

1) *Epidemiology and molecular biology of virus Diseases of grapevine* Rayapati, N.A. 891

Originally Reviewed: 02/28/05

- The committee discussed that the abstract is not informative. Motion to approve pending more details in methodology and re review by primary reviewer.
- 3/11/05: Approved.

2) *Cell Mediated Immune Mechanisms of Cattle in Response* Goff, W.L. 892

*to Babesia Infections*

Originally Reviewed: 02/28/05

- The committee discussed that BCG is listed in BMBL as hazardous to lab personnel and hence on section 3, page 4 of 11, human hazard should be marked. Also, on page 4 of 11, answer to question 5 in the box need to add 'composting' after incineration. IBC Coordinator should call the PI and can do the changes administratively. Motion to approve pending above suggested changes and reviewed by IBC Coordinator.
- 3/02/05: Approved.

3) *Regulation and Function of Small Heat shock Proteins in Cultured Human Cells* Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing biosafety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.
- 12/13/04: Mike Kluzik informed the committee that EH&S is waiting for the PI to submit the biosafety manual with condensed version of blood borne pathogen standard attached.
- 1/31/05: Waiting to hear from the PI.
- 2/28/05: Waiting to hear from the PI.
- 03/21/05: Approved.

3) *Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer* Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria. Motion to defer until the completion of biosafety manual and revision of BAF.
- 11/29/04: Mike Kluzik updated the status of the lab. As soon as the biosafety cabinet is ready, the protocol can be approved.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting to hear about the bio safety cabinet so that the lab can be approved.
- 1/31/05: The PI is waiting for the grants to purchase the cabinet.
- 2/28/05: Waiting to hear from the PI.
- 03/22/05: Approved.

**7. Deferred BAF's**

A) *Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens* Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.
- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.

- 12/13/04: Need to hear from the PI about the abstract.
- 1/31/05: Waiting to hear from the PI.
- 2/28/05: Waiting to hear from the PI.
- 3/28/05: Since the protocol was originally reviewed more than six months back, IBC committee requested the IBC Coordinator to contact the PI and let him know that he needs to submit the abstract within 30 days, and if not he needs to re submit the protocol as a new one.

#### **8. Old Business**

##### **A) Amendment form posted on the website**

Dave informed the committee that the approval on BAF is for 3 yrs. After 3 yrs, the BAF should go through renewal and if there are any modifications within the approval period, needs to go through amendment form. Request for amendment on approved protocol form is now posted on the website at: [http://www.ogrd.wsu.edu/HSANBIO/biosafe/rtf/IBC\\_Ammendment\\_Form3-4-05.rtf](http://www.ogrd.wsu.edu/HSANBIO/biosafe/rtf/IBC_Ammendment_Form3-4-05.rtf). Dave also informed the committee about IBC data base. The current IBC database does not capture the new BAF form details. On April 1<sup>st</sup>, Alex Zetner from OGRD will start working on the new IBC data base. This new data base will be web based.

#### **9. New Business**

None

#### **10. Adjournment:**

**The meeting was adjourned at 1:45 pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**April 25, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Lynn Herrmann, Scott Neils, Steven Russell, Daniel Bradway, Jennifer Hogan, and Malathi Jandhyala.

**ABSENT:** John Dahl, Rob Corcoran, Robert Bogden, Linda Thomashow, [REDACTED] and Hanu Pappu.

**1. MINUTES – March 28, 2005**

Motion to approve by D. Clark and 2<sup>nd</sup> by, S. Neils, passed 6:0

**2. ANNOUNCEMENTS**

None

**3. BSL-1 BAF's**

**A. New Protocols/Modifications**

1) *Microarray Analysis of Altered Activation-Associated*      *Oaks, L. J.*      895

*Gene Expression in Equine Infectious Anemia Virus Infected Macrophages*

Motion to approve by S. Russell, 2<sup>nd</sup> by S. Neils, passed 7:0

2) *Host-Pathogen Interactions in Respiratory Infection*      *Srikumaran, S.*      896

Originally Reviewed: 7/26/04

- The committee discussed that the BAF within has two separate protocols and abstracts. The host for the vectors is not clear. Steve Russell indicated that ASAF for the PI does not cover infecting and euthanizing big horn sheep. Motion to defer clarification with regard to the host for the vectors and splitting the BAF into two BAFs by J. Hogan, 2<sup>nd</sup> by D. Bradway, passed 7:0

**4. BSL-2 BAF's**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

1) *Epidemiology and molecular biology of virus*      *Rayapati, N.A.*      891

*Diseases of grapevine*

Originally Reviewed: 02/28/05

- The committee discussed that the abstract is not informative. Motion to approve pending more details in methodology and re review by primary reviewer.
- 3/11/05: Approved.

2) *Cell Mediated Immune Mechanisms of Cattle in Response*      *Goff, W.L.*      892

*to Babesia Infections*

Originally Reviewed: 02/28/05

- The committee discussed that BCG is listed in BMBL as hazardous to lab personnel and hence on section 3, page 4 of 11, human hazard should be marked. Also, on page 4 of 11, answer to question 5 in the box need to add 'composting' after incineration. IBC Coordinator should call the PI and can do the changes administratively. Motion to approve pending above suggested changes and reviewed by IBC Coordinator.
- 3/02/05: Approved.

**3) Regulation and Function of Small Heat shock Proteins in Cultured Human Cells** Shelden, E. 877

Originally Reviewed: 9/22/04

- 9/22/04: Motion to approve pending submittal section 5 of the BAF and that the PI submit a separate blood borne pathogens plan or should revise the existing biosafety manual to include this plan due to the fact that he is working with human cells.
- 11/29/04: Mike Kluzik updated the status of the manual.
- 12/13/04: Mike Kluzik informed the committee that EH&S is waiting for the PI to submit the biosafety manual with condensed version of blood borne pathogen standard attached.
- 1/31/05: Waiting to hear from the PI.
- 2/28/05: Waiting to hear from the PI.
- 03/21/05: Approved.

**4) Removal of Giardia Intestinales cysts from ground water using a surfactant modified zeolite barrier in a model aquifer** Schulze-Makuch, D. 882

Originally Reviewed: 10/25/04

- The committee discussed that the PI needs to clarify the method of inactivation of biological agent. The PI also needs to clarify the fact that there will be no activities that cause the generation of aerosol. Also, the PI needs to clarify how he would numerate the bacteria. Motion to defer until the completion of biosafety manual and revision of BAF.
- 11/29/04: Mike Kluzik updated the status of the lab. As soon as the biosafety cabinet is ready, the protocol can be approved.
- 12/13/04: Mike Kluzik updated that the EH&S is waiting to hear about the bio safety cabinet so that the lab can be approved.
- 1/31/05: The PI is waiting for the grants to purchase the cabinet.
- 2/28/05: Waiting to hear from the PI.
- 03/22/05: Approved.

**7. Deferred BAF's**

**A) Characterization of Glucanase Inhibitor Proteins: A New Counter Defense Mechanism by Plant Pathogens** Bishop, J. 868

Originally Reviewed: 7/26/04

- The IBC decided to defer this protocol in July. The PI needed to submit a copy of the abstract before the committee could approve.
- 7/27/04: The IBC coordinator emailed the PI to get a copy of the abstract. The PI is working on getting this done.
- 9/13/04: The IBC coordinator emailed the PI to find out the status of the abstract.
- 11/29/04: Sandra Ristow updated the status of the protocol. The committee is still waiting to hear from the PI about the abstract.
- 12/13/04: Need to hear from the PI about the abstract.

- 1/31/05: Waiting to hear from the PI.
- 2/28/05: Waiting to hear from the PI.
- 3/28/05: Since the protocol was originally reviewed more than six months back, IBC committee requested the IBC Coordinator to contact the PI and let him know that he needs to submit the abstract within 30 days, and if not he needs to re submit the protocol as a new one.
- 04/25/05: Motion to remove the protocol from the deferred list and resubmit as new by S. Neils, 2<sup>nd</sup> by L. Herrmann, passed 7:0. The IBC Coordinator will write an e-mail to the PI asking him not to do any work under this protocol unless he resubmits and gets approval.

## **8. Old Business**

### **A) IBC Manual:**

Dave informed the committee that comments on the draft WSU IBC Manual were due April 22, 2005. Only one Professor/Director called to express concerns about APHIS permit requirements. EHS also responded to the IBC manual with written comments. Scott Neils, community member on the IBC committee provided written comments and expressed the need for clarification on the IBC manual with regard to chain of custody and teaching labs.

### **B) Update on IBC Database:**

Dave provided an update about IBC database. The current IBC database does not capture the new BAF form details. In April, Alex Zentner hired by Office of Research has started working on the new IBC database. This new data base will capture the details on the current BAF and have other database improvements. Alex made positive progress on the web based database

## **9. New Business**

None

## **10. Adjournment:**

**The meeting was adjourned at 1:45 pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**May 23, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Scott Neils, Hanu Pappu (via teleconference call), Steven Russell, Linda Thomashow, Daniel Bradway, Jennifer Hogan, John Dahl and Malathi Jandhyala.

**ABSENT:** Lynn Herrmann, Rob Corcoran, Robert Bogden, and [REDACTED]

**1. MINUTES – April 25, 2005**

Motion to approve with correction to minor editorial comments by S. Neils and 2<sup>nd</sup> by, D. Bradway, passed 8:0

**2. ANNOUNCEMENTS**

A) IBC meetings dates for June and July months are June 20<sup>th</sup> and July 18<sup>th</sup>. Sandra will be out of town for June 20<sup>th</sup> meeting. Hanu volunteered to be the interim chair for June 20<sup>th</sup> meeting.

**1. BSL-1 BAF's**

**A. New Protocols/Modifications**

1) *Activation Dependent Restriction of Lentiviral Replication In Macrophages*      *Oaks, L. J.*      897

**Primary Reviewer: L. Herrmann**

**Secondary Reviewer: S. Russell**

Motion to approve by D. Bradway, 2<sup>nd</sup> by S. Russell passed 9:0 (Jennifer Hogan joined the meeting and hence we have 9:0 quorum)

2) *The Effect of Wheat ABA Response Mutants on Grain Dormancy and Drought Tolerance*      *Steber, C. M.*      898

**Primary Reviewer: H. Pappu**

**Secondary Reviewer: L. Thomashow**

Motion to approve by L. Thomashow, 2<sup>nd</sup> by J. Dahl, passed 9:0

3) *Host Cell Receptors for Mannheimia (Pasteurella) Haemolytica Leukotoxin*      *Srikumaran, S.*      899

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: S. Russell**

Motion to approve by S. Russell, 2<sup>nd</sup> by D. Bradway, passed 9:0

4) *Virulence Factors of Mannheimia (Pasteurella) Haemolytica*      *Srikumaran, S.*      900

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: S. Neils**

Motion to approve by J. Hogan, 2<sup>nd</sup> by S. Neils, passed 9:0

5) *Porcine Macrophage Cell-Lines for In Vitro Propagation Of Porcine Reproductive and Respiratory Syndrome Virus*      *Srikumaran, S.*      901

**Primary Reviewer: L. Herrmann**

**Secondary Reviewer: J. Hogan**

Motion to approve by J. Dahl, 2<sup>nd</sup> by D. Bradway, passed 9:0

**B. Renewals**

1) *Enhanced Disease Resistance and Improved Selection for Alfalfa and Other Legumes*      *Larsen, R. C.*      418



**Primary Reviewer: R. Bogden**

**Secondary Reviewer: H. Pappu**

Motion to approve by H. Pappu, 2<sup>nd</sup> by L. Thomashow, passed 9:0

**4. BSL-2 BAF's**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

None

**7. Deferred BAF's**

None

**8. Old Business**

None

**9. New Business**

None

**10. Adjournment:**

Motion passed by L. Thomashow and 2<sup>nd</sup> by J. Hogan 9:0

**The meeting was adjourned at 1:35 pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**June 20, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Lynn Herrmann, Dave Clark, Mike Kluzik, Hanu Pappu (Chair), Steven Russell, Linda Thomashow, and Jennifer Hogan.

**ABSENT:** Sandra Ristow, Rob Corcoran, Daniel Bradway, Robert Bogden, John Dahl, Scott Neils, Malathi Jandhyala, and [REDACTED].

**1. MINUTES – May 23, 2005**

Motion to approve by Steve Russell and 2<sup>nd</sup> by Jennifer Hogan; passed 6:0

**2. ANNOUNCEMENTS**

Malathi had a family emergency and will be out of the office June 15 through July 4, 2005.

**3. BSL-1 BAF's**

**A. New Protocols**

1) *Mapping and Cloning of High Temperature Adult Plant Resistance Genes to Stripe Rust in Wheat* Kidwell, K. K. 902

**Primary Reviewer:** Pappu, H.

**Secondary Reviewer:** Thomashow, L.

The protocol was discussed and a request was made that the PI clarify what activities will be completed at WSU and what activities will be completed at UC-Davis.

Motion to approve by Linda Thomashow, 2<sup>nd</sup> by Lynn Herrmann; passed 6:0.

**B. Renewals**

1) *Mapping the Rainbow Trout Genome* Phillips, R. 732

**Primary Reviewer:** Hogan, J.

**Secondary Reviewer:** Bogden, R.

The protocol was discussed. The committee questioned the source of the trout DNA.

Motion to defer pending clarification of the source of the trout DNA and review by the IBC Coordinator made by Steve Russell, 2<sup>nd</sup> by Lynn Herrmann; passed 6:0.

2) *Potato Variety Development through Gene Transfer and Virology* Brown, C.R. 325

**Primary Reviewer:** Pappu, H.

**Secondary Reviewer:** Thomashow, L.

The protocol was discussed and no concerns were raised.

Motion to approve by Linda Thomashow, 2<sup>nd</sup> by Jennifer Hogan; passed 6:0.

**C. Modifications**

1) *Potato Variety Development through Gene Transfer and Virology* Brown, C.R. 325

**Primary Reviewer:** Pappu, H.

**Secondary Reviewer:** Thomashow, L.

The modification was discussed and no concerns were raised.

Motion to **approve** by Steve Russell, 2<sup>nd</sup> by Linda Thomashow; passed 6:0.

**2) Aquaculture Washington Subproject**

*Thorgaard, G.* 827

**Primary Reviewer:** *Russell, S.*

**Secondary Reviewer:** *Neils, S.*

The modification was discussed and no concerns were raised.

Motion to **approve** by Steve Russell, 2<sup>nd</sup> by Lynn Herrmann; passed 6:0.

**4. BSL-2 BAF's**

**A. New**

**1) *Molecular Biology and Pathogenesis of Retroviruses***

*Carpenter S.* 903

**Primary Reviewer:** *Herrmann, L.*

**Secondary Reviewer:** *Dahl, J.*

The protocol was discussed. Lynn Herrmann had contacted the PI to get clarification on cell lines, genome construct, and vectors. Lynn provided the PI's response to include in the BAF file. Mike Kluzik also contacted the PI to get clarification on the request for BSL-2 level. Mike provided the e-mails for inclusion in the BAF file as well.

Motion to **approve** by Lynn Herrmann, 2<sup>nd</sup> by Dave Clark; passed 6:0.

**B. Renewals**

**None**

**C. Modifications**

**1) *Induction of Cytotoxic T Lymphocytes in Horses***  
*Virology*

*Mealey, R.H.* 876

**Primary Reviewer:** *Bradway, D.*

**Secondary Reviewer:** *Herrman, L.*

The protocol was discussed. There was considerable discussion as to whether the vaccinia virus (vaccine strain) is a BSL-1 or BSL-2 agent. If BSL-2 the BMBL could be interpreted to require smallpox vaccination. However it was unclear whether a) the vaccinia virus requires BSL-2 and 2) whether it made sense to offer the smallpox vaccination if someone is working with vaccinia virus (vaccine strain).

Motion to **defer** pending clarification by the PI and review by the primary and secondary reviewers made by Linda Thomashow, 2<sup>nd</sup> by Jennifer Hogan; passed 6:0.

**5. BSL-3 BAF's**

**None**

**6. Protocols approved in the interim**

**None**

**7. Deferred BAF's**

**None**

**8. Old Business**

**None**

**9. New Business**

None

**10. Adjournment:**

The meeting was adjourned at 2:30pm.

**Next meeting will be held on:**

**July 18<sup>th</sup>, 2005; Neill 416; 1-2:30 p.m.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**July 18, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Sandra Ristow, Mike Kluzik, Scott Neils, Hanu Pappu, Steven Russell, Linda Thomashow, Daniel Bradway, Jennifer Hogan, Robert Bogden, John Dahl, Lynn Herrmann, and Malathi Jandhyala.

**ABSENT:** Rob Corcoran

**1. MINUTES – June 20, 2005**

Motion to approve by L. Herrmann and 2<sup>nd</sup> by, D. Clark; passed 10:0

**2. ANNOUNCEMENTS**

A) [REDACTED] is no longer working at WSU. Program Assistant interviews have started.

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Texture of Maize Kernels Expressing Puroindolines* Morris, C.F. 904

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: H. Pappu**

The protocol was discussed by the committee. Linda mentioned that the work is a collaborative work from Iowa. No field testing is anticipated. Need some expansion on the answers to question 5 and 6 from page 7 of 10 of the application. The PI needs to clarify what are the normal greenhouse controls.

Motion to defer pending clarification to implementation of physical and biological containment conditions and it should be stated according to guidelines and re reviewe by primary and secondary reviewers by L. Thomashow and 2<sup>nd</sup> by S.Neils; passed 11:0.

2) *A Program of Research in Population Cytogenetics* Hassold, T. 906

**Primary Reviewer: R. Bogden**

**Secondary Reviewer: J. Hogan**

The protocol was discussed and no concerns were raised.

Motion to approve by D. Bradway, 2<sup>nd</sup> by J. Hogan; passed 11:0

3) *Cytogenetic Analysis of Recombination in the Human Male* Hassold, T. 907

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: S. Russell**

The protocol was discussed and no concerns were raised.

Motion to approve by S. Russell, 2<sup>nd</sup> by R. Bogden; passed 11:0

4) *Respiration, Polymer Synthesis and Effectiveness in Symbiotic Nitrogen Fixation* Kahn, M. L. 908

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: H. Pappu**

The protocol was discussed and no concerns were raised.

Motion to approve by L.Thomashow, 2<sup>nd</sup> by D. Bradway; passed 11:0.

**B. Renewals**

None

**C. Modifications**

None

**2. BSL-2 BAF's**

**A. New Protocols**

1) *Pilot Study of Circadian Rhythm's, Sleep and Cytokines  
In Childhood Acute Lymphoblastic Leukemia (ALL)*

*Kruger, J. M. 905*

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: L. Herrmann**

John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.

Motion to defer pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons by L. Thomashow and 2<sup>nd</sup> by L. Herrmann; passed 11:0.

**B. Renewals**

1) *Host cellular Pathways Activated by Trichinella Spiralis*

*Jasmer, D.P. 381*

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: L. Herrmann**

The protocol was discussed and the committee felt that not much has changed except in page 5 of 10 there was mention about 293 mammalian cells. The committee requested Mike Kluzik to send in the human cell line addendum to the PI.

Motion to approve by R. Bogden, 2<sup>nd</sup> by D. Bradway; passed 11:0.

**5. BSL-3 BAF's**

**None**

**6. Protocols approved in the interim**

None

**7. Deferred BAF's**

**None**

**8. Old Business**

A) IBC chair Sandra Ristow responded to Scott Neils's (WSU IBC community representative) comments on the draft IBC manual (3/21/05) with respect to concerns regarding the oversight of teaching labs and chain of custody of biological materials. Scott's comments were forwarded to Vice Provost of Research, Jim Petersen.

With respect to concerns regarding oversight of teaching labs.

The VPR believes that the IBC primarily oversees research and diagnostic activities involving biological materials (as defined in the draft IBC Manual). The VPR is concerned about the oversight of teaching labs and has sent a memorandum to the President and Provost (Petersen to Rawlins and Bates, April 11, 2005) requesting that a separate mechanism be implemented to oversee teaching labs. The responsibility for oversight of teaching labs will be resolved and designated via policy or memorandum from the appropriate WSU authority.

With respect to concerns regarding Chain-of-Custody (COC) of biological materials. The VPR is also very concerned about this issue and is looking to the IBC, the Biosafety Officer (BSO), and Shipping & Receiving to help identify appropriate solutions to this complex problem. A mechanism for centralized approval and tracking of all biological materials entering WSU facilities is a long-term goal of the VPR. However, implementation of such a system will take time and resources. Hopefully, incremental continuous improvements will be made toward this goal. In addition, the CDC/NIH manual, *Biosafety in Microbiological and Biomedical Laboratories* (BMBL) is currently under revision to include a chapter on biosecurity that may help provide guidance on this issue. Also, the inaugural meeting of the National Science Advisory Board on Biosecurity (NSABB) was held Thursday, June 30, and Friday, July 1, 2005. This board is expected to make recommendations regarding biosecurity that will aid in producing procedures and policies. At this time, the VPR agrees with the approach begun in the draft IBC Manual, which is to begin to raise the level of awareness of WSU researchers regarding security (including COC) of biological materials.

#### **9. New Business**

FYI...Recommendation for field Trials (GMO plants) from National Agricultural biotechnology council meeting at Nashville meeting. The committee was asked to look over the recommendations.

#### **10. Adjournment:**

Motion passed by S. Neils; passed 11:0.

**The meeting was adjourned at 2:10 pm**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**August 29, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Dave Clark, Rob Corcoran, Sandra Ristow, Mike Kluzik, Hanu Pappu, Steven Russell, Linda Thomashow, Jennifer Hogan, Lynn Herrmann, and Malathi Jandhyala.

**ABSENT:** Scott Neils, Daniel Bradway, John Dahl, and Robert Bogden

**GUESTS:** Rebecca Van Wyck and Jim Petersen

**1. MINUTES – July 18, 2005**

Motion to approve by H. Pappu and 2<sup>nd</sup> by, S. Russell; passed 6:0

(Linda Thomashow joined the meeting after the minutes)

**2. ANNOUNCEMENTS**

A) Rebecca Van Wyck, new program assistant at the Research Compliance Office was introduced to the committee.

B) Sandra gave an update on Biosafety Officer search. The deadline for the application process is September 19<sup>th</sup>. So far three applicants responded from Moscow and Pullman area. The position may be re advertised.

C) Mike Kluzik informed the committee about the renewal notifications. IBC used to send renewal notices on expiring MUA's every year. This procedure was discontinued for some years. Recently, the first batch of renewal notices was sent for September month expiring BAF's'.

D) Dr. Jim Petersen emphasized the importance of WSU IBC's role in protecting the public, faculty, employees, students, and the University. He thanked the committee members for their dedication and service. He reiterated the importance of the IBC manual in communicating this information to the WSU community. Dr. Petersen asked that committee discuss and address various issues regarding the review of genetically modified organisms, select agents, teaching labs, and diagnostic labs.

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Regulation of Expression of Classical and Non-classical MHC Class I Genes in Bovine Trophoblast Cells* Davies, C. J. 910

**Primary Reviewer: S. Russell**

**Secondary Reviewer: L. Herrmann**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by S. Russell, 2<sup>nd</sup> by L. Herrmann; passed 7:0.

**B. Renewals**

1) *Control of Storage Protein Biosynthesis of mRNA Targeting* Okita, T. W. 384

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: R. Bogden**

Linda talked briefly about the protocol. She pointed out that the abstract is incomplete in methodology. The PI needs to give more detail information on what is being cloned and what are the procedures involved in the experiment.



Motion to defer pending clarification to what is being cloned and elaboration in procedures and re reviewed by the primary reviewer by **L. Thomashow** and 2<sup>nd</sup> by **J. Hogan**; passed 7:0

2) *Molecular Mechanisms of MSP2 Variation in Rickettsia* Palmer, G. H. 586

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: J. Hogan**

Jennifer Hogan gave a brief introduction to the protocol. On the application under facilities description, LARC was given for holding the mice. Steve Russell informed the committee that LARC does not have facilities to hold the mice. The PI needs to remove this from the application. If the PI agrees to the suggested change, IBC Coordinator can implement the change administratively. On page 4 of 10, question 4 needs to elaborate on the standard procedures.

Motion to defer pending clarification elaboration with regards to standard procedures for question 4 on page 4 of the application and deleting LARC as holding facility for mice and re reviewed by IBC Coordinator by **L. Herrmann** and 2<sup>nd</sup> by **J. Hogan**; passed 7:0

3) *Genome-wide Analysis of Transcription Factors and Chromatin in Yeast* Wyrick, J. 793

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: R. Bogden**

The IBC committee did not have any concerns over the protocol.

Motion to approve by **L. Thomashow**, 2<sup>nd</sup> by **H. Pappu**; passed 7:0.

4) *Functional Analysis of Human MutS Homologous Proteins, hMSH4 and hMSH5* Her, C. 772

**Primary Reviewer: J. Hogan**

**Secondary Reviewer: D. Bradway**

Jennifer Hogan gave an overview of the project. The committee felt that section 5 on the application should clarify the use of human cell line. Prior to the IBC meeting, PI contacted Mike Kluzik and was told by Mike that he needs to submit updated biosafety manual and include blood borne pathogen training. The PI also needs to fill out section 5 and delete section 3 on the application form.

Motion to defer pending submission of updated biosafety manual with BBP training and completion of section 5 on the application and re reviewed by Malathi by **J. Hogan** and 2<sup>nd</sup> by **L. Thomashow**; passed 7:0.

5) *Genome Analysis of Wheat and Other Grasses* Gill, K.S. 794

**Primary Reviewer: H. Pappu**

**Secondary Reviewer: L. Thomashow**

The primary, secondary reviewers and the committee did not have any concerns over the protocol.

Motion to approve by **H. Pappu**, 2<sup>nd</sup> by **S. Russell**; passed 7:0.

### C. Modifications

None

## **2. BSL-2 BAF's**

### A. New Protocols

1) *Gene Silencing using Lentiviral siRNA Vectors* Griswold, M. D. 909

**Primary Reviewer: L. Herrmann**

**Secondary Reviewer: S. Neils**

Lynn discussed the project with the committee. Her major concerns were with regards to Animal biosafety lab containment level and biosafety cabinet. NIH guidelines and the manufacture for the

assay indicate the need of BSL-2 facility. The committee concurred with the concerns and motioned to defer the protocol until the concerns are taken care of

Motion to defer pending changing the laboratory containment from ABSL-1 to ABSL-2 and acquisition of biosafety cabinet by L. Herrmann and 2<sup>nd</sup> by L. Thomashow; passed 7:0.

#### **B. Renewals**

None

#### **C. Modifications**

None

#### **5. BSL-3 BAF's**

None

#### **6. Protocols approved in the interim**

1) *Texture of Maize Kernels Expressing Puroindolines* Morris, C.F. 904

Originally reviewed on July 18, 2005:

- The protocol was discussed by the committee. Linda mentioned that the work is a collaborative work from Iowa. No field testing is anticipated. Need some expansion on the answers to question 5 and 6 from page 7 of 10 of the application. The PI needs to clarify what are the normal greenhouse controls. Motion to defer pending clarification to implementation of physical and biological containment conditions and it should be stated according to guidelines and re reviewed by primary and secondary reviewers.
- 8/29/05: The PI provided the clarifications. The primary and secondary reviewers reviewed and approved the study.

#### **7. Deferred BAF's**

1) *Pilot Study of Circadian Rhythm's, Sleep and Cytokines* Kruger, J. M. 905  
*In Childhood Acute Lymphoblastic Leukemia (ALL)*

Originally reviewed on July 18, 2005:

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to defer pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.
- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.

#### **8. Old Business**

##### **a) IBC Manual**

Dave requested the committee members to review the updated IBC manual and provide input by first week of September.

**9. New Business**

None

**10. Adjournment**

Motion passed by H.Pappu; passed 7:0.

**Next meeting will be on September 19th from 1:10 to 2:30 pm at Neill 416.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**September 19, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Scott Neils, Daniel Bradway, John Dahl, Robert Bogden, Sandra Ristow, Mike Kluzik, Linda Thomashow, Jennifer Hogan, Lynn Herrmann, and Malathi Jandhyala.

**ABSENT:** Dave Clark, Hanu Pappu, Steven Russell, and Rob Corcoran.

**GUESTS:** Rebecca Van Wyck and Dan Dreesmann

**1. MINUTES – August 29, 2005**

Motion to approve by **L. Herrmann** and 2<sup>nd</sup> by **J. Hogan**; passed 8:0

**2. ANNOUNCEMENTS**

A) Mike Kluzik reported an incident that occurred at food disease investigation unit. A time slip at the unit was admitted in the hospital with E.Coli infection and later released. The cause of the exposure is not yet known. Mike stressed the importance of good biosafety practices.

B) The community member, Scott Neils will be stepping down from the IBC starting Oct 1<sup>st</sup>, 2005. He will be moving out of Pullman.

C) Sandra introduced Dan Dreesmann from plant growth facilities. Dan will be an observer and will be attending the IBC meetings regularly.

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Phenylpropanoid Pathway Networks: An Integrated Approach to Establishing Protein/Enzyme Function in Arabidopsis and Their Associated Networks* *Lewis, N.G.* **911**

**Primary Reviewer: D. Bradway**      **Secondary Reviewer: J. Dahl**  
Primary and secondary reviewers did not have any concerns over the protocol.  
Motion to approve by **D. Bradway**, 2<sup>nd</sup> by **R. Bogden**; passed 8:0.

2) *Deciphering the Complex Networks in Monolignol Formation, Phenylpropanoid Coupling and Lignin Assembly: An Integrative Approach* *Lewis, N.G.* **912**

**Primary Reviewer: D. Bradway**      **Secondary Reviewer: L. Herrmann**  
Primary and secondary reviewers did not have any concerns over the protocol.  
Motion to approve by **L. Thomashow**, 2<sup>nd</sup> by **J. Dahl**; passed 8:0.

3) *Molecular Definition of the Unique Phenylpropanoid Radical Coupling Mechanisms of Dirigent Proteins, their Homologues and Associated Metabolism: A Discovery-Based* *Lewis, N.G.* **913**

*Approach*

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: S. Neils**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by R. Bogden, 2<sup>nd</sup> by S. Neils; passed 8:0.

4) *Genetic Modulation of Chlorogenic Acid Levels in Tobacco Stem and Leaf Tissue*

*Lewis, N.G.*

**914**

**Primary Reviewer: H. Pappu**

**Secondary Reviewer: J. Hogan**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by L. Thomashow, 2<sup>nd</sup> by J. Hogan; passed 8:0.

**B. Renewals**

1) *Cloning of the Barley Transcription Factor ANT13*

*Von Wettstein, D.*

**708**

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: R. Bogden**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by R. Bogden, 2<sup>nd</sup> by L. Thomashow; passed 8:0.

2) *Biochemistry of Plant Terpenoids (Hatch Project 0268)/Terpene Metabolism in Mint (Washington Commodity Grant 5268)*

**290**

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: L. Herrmann**

Linda Thomashow felt that composting will not be an adequate method to dispose the waste. The Committee discussed and decided that autoclaving is a better method to dispose. Mike Kluzik brought out the point of perception by customers with regards to genetically modified plant material. Mike is going to talk to Rich Finch, WSU Compost Facility Manager and let IRB Coordinator know about the communication.

Motion to defer until the investigator implements autoclaving as a method of disposing the genetically modified waste and Mike will contact the WSU compost Facility Manager with regards to perception question and re review by IBC Coordinator by L. Thomashow, 2<sup>nd</sup> by R. Bogden; passed 8:0

(Robert Bogden left the meeting)

3) *Biosynthesis of Taxol (NIH Project CA55254)/Diterpene*

*Croteau, R.*

**659**

*Biosynthesis in Taxol Production and Conifer Defense (McIntire-Stennis Project 0967)*

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: J. Hogan**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by D. Bradway, 2<sup>nd</sup> by L. Herrmann; passed 7:0.

4) *Enzymatic Cyclization to Terpenoid Natural Products (NIH GM31354)*

*Croteau, R.*

**664**

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: S. Neils**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by D. Bradway, 2<sup>nd</sup> by J. Dahl; passed 7:0.

**C. Modifications**

None

**2. BSL-2 BAF's**

**A. New Protocols**

None

**B. Renewals**

None

**C. Modifications**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

**1) Molecular Mechanisms of MSP2**

*Palmer, G. H.*

**586**

**Variation in Rickettsia**

Originally reviewed on August 29, 2005:

- Jennifer Hogan gave a brief introduction to the protocol. On the application under facilities description, LARC was given for holding the mice. Steve Russell informed the committee that LARC does not have facilities to hold the mice. The PI needs to remove this from the application. If the PI agrees to the suggested change, IBC Coordinator can implement the change administratively. On page 4 of 10, question 4 needs to elaborate on the standard procedures. Motion to defer pending clarification elaboration with regards to standard procedures for question 4 on page 4 of the application and deleting LARC as holding facility for mice and re reviewed by IBC Coordinator.

- 9/12/05: **Approved**

**2) Control of Storage Protein Biosynthesis of mRNA Targeting**

*Okita, T. W.*

**384**

Originally reviewed on August 29, 2005:

- Linda talked briefly about the protocol. She pointed out that the abstract is incomplete in methodology. The PI needs to give more detail information on what is being cloned and what are the procedures involved in the experiment.
- 9/14/05: The PI provided the needed information and the primary reviewer **approved** the protocol.

**7. Deferred BAF's**

**1) Pilot Study of Circadian Rhythm's, Sleep and Cytokines In Childhood Acute Lymphoblastic Leukemia (ALL)**

*Kruger, J. M.* **905**

Originally reviewed on July 18, 2005:

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to **defer** pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of

measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.

- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.

2) *Gene Silencing using Lentiviral siRNA Vectors*

*Griswold, M. D.*

909

Originally reviewed on August 29, 2005:

- Lynn discussed the project with the committee. Her major concerns were with regards to Animal biosafety lab containment level and biosafety cabinet. NIH guidelines and the manufacture for the assay indicate the need of BSL-2 facility. The committee concurred with the concerns and motioned to defer the protocol until the concerns are taken care of Motion to defer pending changing the laboratory containment from ABSL-1 to ABSL-2 and acquisition of biosafety cabinet.
- 9/19/05: Lynn informed the committee that the manufacture of the assay suggested BSL-2 containment. The committee extended the recommendation to ABSL-2 facility. As per the recommendations by the reviewer, biosafety cabinet has been acquired and it needs to be approved by Mike Price prior to IBC approval of the BAF. Motion to defer pending certification by L. Thomashow, 2<sup>nd</sup> by S. Neills; passed 8:0

3) *Functional Analysis of Human MutS Homologous Proteins, hMSH4 and hMSH5*

*Her, C.*

772

Originally reviewed on August 29, 2005:

- Jennifer Hogan gave an overview of the project. The committee felt that section 5 on the application should clarify the use of human cell line. Prior to the IBC meeting, PI contacted Mike Kluzik and was told by Mike that he needs to submit updated biosafety manual and include blood borne pathogen training. The PI also needs to fill out section 5 and delete section 3 on the application form. Motion to defer pending submission of updated biosafety manual with BBP training and completion of section 5 on the application and re reviewed by Malathi Jandhyala.
- 08/30/05: The PI submitted the BAF with section 5 completed. Need updated biosafety manual with BBP training.
- 9/19/05: Still waiting to hear about the training.

**8. Old Business**

1) Jim Petersen looked at the IBC manual. Both IBC manual and OGRD memo # 13 will be sent out for distribution soon

**9. New Business**

None

**10. Adjournment**

Motion passed by S. Neills; passed 7:0.

**Next meeting will be on October 24 from 1:10 to 2:30 pm at Neill 416.**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**October 24, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Daniel Bradway, John Dahl, Sandra Ristow, Linda Thomashow, Jennifer Hogan, Hanu Pappu, Dave Clark, Malathi Jandhyala, Rebecca Van Wyck and Steven Russell.

**ABSENT:** Lynn Herrmann, [REDACTED] Robert Bogden, Mike Kluzik, and Rob Corcoran.

**GUESTS:** Dan Dreesmann

**1. MINUTES – September 19, 2005**

Add date to minutes, Motion to approve with one edit by S. Russell and 2<sup>nd</sup> by, L. Thomashow; passed 7:0

**2. ANNOUNCEMENTS**

A) Jennifer Hogan is joining the IBC meeting from Spokane via Poly Cam facility.

B) Sandra will not be able to attend the November Pre-IBC and IBC meetings and Hanu Pappu volunteered to be the interim Chair for the month of November.

C) The committee discussed about the upcoming biosafety officer interviews on 10/28/05 and 10/31/05. Two candidates will be interviewed. IBC members are encouraged to meet the candidates.

D) Community member John Eschelmann will be attending the IBC meeting from next month onwards..

(Dan Bradway Joined the meeting)

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Genetic Transforamtion of Fungal Pathogens of Cool Season Grain Legumes* Weidong, C. 915

**Primary Reviewer: J. Hogan**

**Secondary Reviewer: J. Dahl**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by J. Dahl, 2<sup>nd</sup> by L. Thomashow; passed 8:0.

2) *Development of Transgenic Barley Cultivars Expressing Endochitinase, with Resistance to Rhizoctonia Root Rot* Von Wettstein, D. 916

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: H. Pappu**

The primary reviewer discussed the protocol. Dan Bradway questioned if the committee should be concerned with regards to other barley growing in the area. Linda Thomashow suggested that PI needs to give clarification or solution to cross contamination of barley (might need buffer or growth chamber). Also, the PI should submit an abstract. H. Pappu did not have any major comments. The committee needs clarifications on these issues:

a) An abstract b) Verify the green house c) plan or need to avoid out crossing in greenhouse.



The primary reviewer will contact the PI.

Motion to defer pending clarifications suggested by the committee and re review by primary by L. Thomashow, 2<sup>nd</sup> by H. Pappu; passed 8:0.

3) *Engineering Wheat for Improved Nitrogen use Efficiency (NUE) and dietary health* Von Wettstein, D. 918

**Primary Reviewer: H. Pappu**

**Secondary Reviewer: L. Thomashow**

H. Pappu discussed the protocol and expressed concern that the abstract was incomplete and difficult to understand. L. Thomashow wanted clarification on Page 7 of 10 Section 6 questions 5 & 6. Question five should have a full answer. Regarding Question six, L. Thomashow wanted to check if the PI would be doing anything besides Tissue culture, and to add a line indicating that the materials will be destroyed at the end of the study. The following clarifications are needed:

a) A more explicit abstract is needed

b) More complete answers on Page 7 of 10 Section 6 questions 5 & 6.

The primary reviewer will contact the PI.

Motion to defer pending clarifications suggested by the committee and re reviewed by primary by L. Thomashow, 2<sup>nd</sup> by D. Bradway; passed 8:0

## **B. Renewals**

1) *Peptide Signaling in Plants*

Ryan, C. 69

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: R. Bogden**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by D. Bradway, 2<sup>nd</sup> by L. Thomashow; passed 8:0.

2) *FSH and Retinoid Signaling in the Testis*

Kim, K. H. 533

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: S. Russell**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by S. Russell, 2<sup>nd</sup> by D. Bradway; passed 8:0.

3) *Breeding and Genetics of Barley / Molecular Breeding And Genetic Analysis of Improved Malting Barley*

Ullrich, S. 778

**Primary Reviewer: J. Hogan**

**Secondary Reviewer: H. Pappu**

Jennifer did not find any major concerns except summary was little short. Hanu felt it was fine.

Motion to approve by D. Bradway, 2<sup>nd</sup> by H. Pappu; passed 8:0.

4) *Biochemistry of two FADH2-Utilizing Trichlorophenol-4-Monooxygenases*

Xun, L. 791

**Primary Reviewer: R. Bogden**

**Secondary Reviewer: S. Ristow**

S. Ristow read Robert Bogden's comments. Both reviewers felt that there are no major concerns regarding the protocol.

Motion to approve by D. Bradway, 2<sup>nd</sup> by L. Thomashow; passed 8:0.

(Malathi Jandhyala joined the meeting)

5) *Enhancing Winter Wheat for Cold Hardiness*

Skinner, D. Z. 805

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: H. Pappu**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by J. Dahl, 2<sup>nd</sup> by H. Pappu; passed 8:0.

6) *Chimeric Ca2+/Calmodulin-dependent Protein Kinase Mediated Signaling in Plants*

Poovaiah, B.W. 655

**Primary Reviewer: I. Thomashow**

**Secondary Reviewer: H. Pappu**

L. Thomashow informed the committee that she asked the PI to clarify which plants he will be using and the PI updated that information on the application form. H.Pappu did not have major concerns.

Motion to approve by S. Russell, 2<sup>nd</sup> by H. Pappu; passed 8:0.

**C. Modifications**

1) *Host Cell Receptors for Mannheimia (Pasteurella) Haemolytica Leukotoxin*

*Srikumaran, S. 899*

**Primary Reviewer: S. Russell**

**Secondary Reviewer: D. Bradway**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by L. Thomashow, 2<sup>nd</sup> by J. Dahl; passed 8:0.

2) *Porcine Macrophage Cell-Lines for In Vitro Propagation of Porcine Reproductive and Respiratory Syndrome Virus*

*Srikumaran, S. 901*

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: S. Russell**

The primary reviewer saw that the PI is intending to use human cell lines and communicated with the PI that he needs to have a blood borne pathogen plan in the manual and have the lab people sign off on the manual. The PI communicated with Mike and updated the manual and will be training his lab personnel. Becca read Mike's e-mail. S. Russell did not have major concerns.

Motion to approve by D. Bradway, 2<sup>nd</sup> by S. Russell; passed 8:0.

**2. BSL-2 BAF's**

**A. New Protocols**

1) *High Resolution Ion Mobility Mass Spectrometry (IMMS) for Measuring and Monitoring Metabolomes*

*Hill, H. 917*

**Primary Reviewer: J. Hogan**

**Secondary Reviewer: J. Dahl**

Dr. Hill's lab contact Kim Kaplan sent the copy of biosafety manual to Chris Baylon on October 13, 2005. Chris Baylon sent an e-mail to the PI to address some concerns with regards to biosafety manual. Jennifer Hogan had questions with regards to transport plan of the samples. She communicated her concerns to the PI's lab contact [REDACTED]. [REDACTED] has responded in an e-mail. The secondary reviewer agreed with the comments of primary. The committee wanted a clarification on these points a) update the BBP with transport plan of the samples b) completed biosafety manual with revisions requested by Chris Baylon c) perchloric acid hood (Mike is working on it).

Motion to defer pending clarifications to the reviewers' points mentioned above and re-reviewed by primary and secondary by L.Thomashow, 2<sup>nd</sup> by J. Hogan; passed 8:0.

**B. Renewals**

1) *Determination of the Pathogenicity of Campylobacter*

*Dhillon, A.S. 804*

**Primary Reviewer: S. Ristow**

**Secondary Reviewer: D. Bradway**

The primary reviewer did not have major issues; ASAF number needs to be filled out on the BAF. This can be taken care administratively. Dan Bradway did not see any problems.

Motion to approve by D. Bradway and 2<sup>nd</sup> by S. Russell; passed 8:0

**C. Modifications**

None

## **5. BSL-3 BAF's**

None

## **6. Protocols approved in the interim**

1) *Biochemistry of Plant Terpenoids (Hatch Project 0268)/Terpene Metabolism in Mint (Washington Commodity Grant 5268)* Croteau, R. 290

- Linda Thomashow felt that composting will not be an adequate method to dispose the waste. The Committee discussed and decided that autoclaving is a better method to dispose. Mike Kluzik brought out the point of perception by customers with regards to genetically modified plant material. Mike is going to talk to Rich Finch, WSU Compost Facility Manager and let IRB Coordinator know about the communication. Motion to **defer** until the investigator implements autoclaving as a method of disposing the genetically modified waste and Mike will contact the WSU compost Facility Manager with regards to perception question and re review by IBC Coordinator.
- 9/20/05: Mike Wildung from Dr. Croteau's lab talked with IBC green house personnel and they will start discarding transgenic plant material after autoclaving. **Approved**

2) *Gene Silencing using Lentiviral siRNA Vectors* Griswold, M. D. 909  
Originally reviewed on August 29, 2005:

- Lynn discussed the project with the committee. Her major concerns were with regards to Animal biosafety lab containment level and biosafety cabinet. NIH guidelines and the manufacture for the assay indicate the need of BSL-2 facility. The committee concurred with the concerns and motioned to defer the protocol until the concerns are taken care of. Motion to **defer** pending changing the laboratory containment from ABSL-1 to ABSL-2 and acquisition of biosafety cabinet.
- 10/13/05: Biosafety cabinet was certified and minor edits were taken care. **Approved.**

## **7. Deferred BAF's**

1) *Pilot Study of Circadian Rhythm's, Sleep and Cytokines In Childhood Acute Lymphoblastic Leukemia (ALL)* Kruger, J. M. 905

Originally reviewed on July 18, 2005:

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to **defer** pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.
- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.

2) *Functional Analysis of Human MutS Homologous Proteins, hMSH4 and hMSH5* Her, C. 772

Originally reviewed on August 29, 2005:

- Jennifer Hogan gave an overview of the project. The committee felt that section 5 on the application should clarify the use of human cell line. Prior to the IBC meeting, PI contacted Mike Kluzik and was told by Mike that he needs to submit updated biosafety manual and include blood borne pathogen training. The PI also needs to fill out section 5 and delete section 3 on the application form. Motion to defer pending submission of updated biosafety manual with BBP training and completion of section 5 on the application and re reviewed by Malathi Jandhyala.
- 08/30/05: The PI submitted the BAF with section 5 completed. Need updated biosafety manual with BBP training.

**8. Old Business**

None

**9. New Business**

None

**10. Adjournment**

Motion passed by L. Thomashow; passed 7:0.

**Next meeting will be on November 14, 2005 from 1:10 to 2:30 pm at Neill 416 in Pullman and WSU Spokane (SHSB 210F).**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**November 14, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416**

**PRESENT:** Linda Thomashow, Jennifer Hogan, Hanu Pappu, [REDACTED], Rob Corcoran, Lynn Herrmann, Dave Clark, Malathi Jandhyala, Mike Kluzik, and Steven Russell.

**ABSENT:** Sandra Ristow, Daniel Bradway, John Dahl, and Robert Bogden.

**GUESTS:** Dan Dreesmann

**1. MINUTES – October 24, 2005**

John's last name should be corrected, Motion to approve with one edit by L. Thomashow, 2nd by S. Russell; passed 6:0

**2. ANNOUNCEMENTS**

A) [REDACTED] was welcomed by Hanu Pappu.

B) Dave, Mike, Sandra and Malathi made some minor corrections on the Biosafety approval form. Sandra approved the corrections. The updated version is posted on the web. Lynn Herrmann requested if the form can be made available in PDF also since most of the Mac users can not download the application in RTF. Dave will try to talk to Monte Sutton, IT person for RCO about the feasibility of the above request. (Dave made this announcement at the end of the meeting)

(Dave Clark Joined the meeting)

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Transcript - Based Cloning of Genes Involved in Chloroplast Development* Von Wettstein, D. 919

**Primary Reviewer: L. Thomashow**

**Secondary Reviewer: H. Pappu**

Primary and secondary reviewers did not have any concerns over the protocol.  
Motion to approve by L. Thomashow, 2<sup>nd</sup> by H. Pappu; passed 7:0.

**B. Renewals**

1) *Improving Suicide Genes for Cancer Gene Therapy* Black, M. 620

*Engineering Enzymes for Anti-Tumor Suicide Gene Therapy*

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: L. Herrmann**

The primary reviewer was absent at the meeting and L. Herrmann discussed the protocol. Overall the protocol is fine; However the PI needs to give clarifications to the following:

- a) On the application, Section 4, need to clarify what type of containment level will be used
- b) On the application, the PI stated that "mammalian cells will be used". Need to clarify if these cells are human or otherwise.

- c) If these cells are human, need to make sure that BL-2 practices are followed and biosafety manual, and blood borne pathogen plan should be in place. Need to work with Mike Kluzik regarding these issues.

Motion to defer pending clarifications suggested by the committee and re review by IBC Coordinator and Mike Kluzik (if the cells are from human cell line) by L. Herrmann, 2<sup>nd</sup> by J. Hogan; passed 7:0.

### C. Modifications

None

### 2. BSL-2 BAF's

None

### B. Renewals

None

### C. Modifications

None

### 5. BSL-3 BAF's

None

### 6. Protocols approved in the interim

1) *Biochemistry of Plant Terpenoids (Hatch Project 0268)/Terpene Metabolism in Mint (Washington Commodity Grant 5268)* Croteau, R. 290

- Linda Thomashow felt that composting will not be an adequate method to dispose the waste. The Committee discussed and decided that autoclaving is a better method to dispose. Mike Kluzik brought out the point of perception by customers with regards to genetically modified plant material. Mike is going to talk to Rich Finch, WSU Compost Facility Manager and let IRB Coordinator know about the communication. Motion to **defer** until the investigator implements autoclaving as a method of disposing the genetically modified waste and Mike will contact the WSU compost Facility Manager with regards to perception question and re review by IBC Coordinator.
- 9/20/05: Mike Wildung from Dr. Croteau's lab talked with IBC green house personnel and they will start discarding transgenic plant material after autoclaving. **Approved**

2) *Gene Silencing using Lentiviral siRNA Vectors* Griswold, M. D. 909  
Originally reviewed on August 29, 2005:

- Lynn discussed the project with the committee. Her major concerns were with regards to Animal biosafety lab containment level and biosafety cabinet. NIH guidelines and the manufacture for the assay indicate the need of BSL-2 facility. The committee concurred with the concerns and motioned to defer the protocol until the concerns are taken care of Motion to **defer** pending changing the laboratory containment from ABSL-1 to ABSL-2 and acquisition of biosafety cabinet.
- 10/13/05: Biosafety cabinet was certified and minor edits were taken care. **Approved.**

### 7. Deferred BAF's

1) *Pilot Study of Circadian Rhythms, Sleep and Cytokines In Childhood Acute Lymphoblastic Leukemia (ALL)* Kruger, J. M. 905

Originally reviewed on July 18, 2005:

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to defer pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.
- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.

2) *Functional Analysis of Human MutS Homologous Proteins, hMSH4 and hMSH5* Her, C.

772

Originally reviewed on August 29, 2005:

- Jennifer Hogan gave an overview of the project. The committee felt that section 5 on the application should clarify the use of human cell line. Prior to the IBC meeting, PI contacted Mike Kluzik and was told by Mike that he needs to submit updated biosafety manual and include blood borne pathogen training. The PI also needs to fill out section 5 and delete section 3 on the application form. Motion to defer pending submission of updated biosafety manual with BBP training and completion of section 5 on the application and re reviewed by Malathi Jandhyala.
- 08/30/05: The PI submitted the BAF with section 5 completed. Need updated biosafety manual with BBP training.

3) *High Resolution Ion Mobility Mass Spectrometry (IMMS) for Measuring and Monitoring Metabolomes* Hill, H.

917

Originally reviewed on October 24, 2005:

- Dr. Hill's lab contact [REDACTED] sent the copy of biosafety manual to Chris Baylon on October 13, 2005. Chris Baylon sent an e-mail to the PI to address some concerns with regards to biosafety manual. Jennifer Hogan had questions with regards to transport plan of the samples. She communicated her concerns to the PI's lab contact [REDACTED]. [REDACTED] has responded in an e-mail. The secondary reviewer agreed with the comments of primary. The committee wanted a clarification on these points a) update the BBP with transport plan of the samples b) completed biosafety manual with revisions requested by Chris Baylon c) perchloric acid hood (Mike is working on it). Motion to defer pending clarifications to the reviewers' points mentioned above and re-reviewed by primary and secondary reviewers.
- 10/27/05: The PI's lab contact [REDACTED] submitted the manual with revisions. Chris Baylon approved the manual with revisions. Chris had the following questions for [REDACTED]:
  - a) Chris communicated that they do not have a record of a perchloric acid hood in Eastlick 390. Need to make sure if it is really a perchloric acid hood or just a normal fume hood in Eastlick 390. Chris also mentioned that this will not matter if the conditions he mentioned about not heating the acid or using large quantities are met. Use of a standard fume hood will be acceptable under these conditions.
  - b) It is not clear if blood samples being transported from Eastlick to Troy will be disinfected before transporting. If not, Troy312 will need to be inspected as a BSL-2

lab as well as Eastlick 390. Eastlick 390 will need to be inspected for approval for use as a BSL-2 lab. Troy 312 will also need to be inspected if infectious agents will be used there. The PI needs to contact Chris Baylon to schedule inspections.

#### **8. Old Business**

##### **A) BSO Search:**

The BSO search committee interviewed two candidates. Dr. Petersen met the candidates. Dave Clark will contact one of the candidates since CHR has Okayed the process. Most likely, the post will be filled by December 1<sup>st</sup> week.

##### **B) WSU Bio Safety Manual:**

OGRD memo # 13 will be revised (the last revision was made in 1987) and send to Dr. Jim Petersen along with the Manual for approval. After the approval from Dr. Petersen, the IBC manual along with memo # 13 will be circulated to the faculty and Staff and also posted on the IBC website.

#### **9. New Business**

None

#### **10. Adjournment**

Motion passed by L. Thomashow; passed 7:0. Meeting was adjourned at 1:30 PM.

Next meeting will be on December 12, 2005 from 1:10 to 2:30 pm at Neill 416 in Pullman and WSU Spokane (SHSB 320 R).



**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**December 12, 2005**  
**1:10-2:30 pm**  
**Neill Hall 416 and WSU Spokane (SHSB 320 R)**

**PRESENT:** Sandra Ristow, Linda Thomashow, Jennifer Hogan, [REDACTED], Lynn Herrmann, Dave Clark, Malathi Jandhyala, Mike Kluzik, and Steven Russell.

**ABSENT:** Hanu Pappu, Rob Corcoran, John Dahl, and Daniel Bradway, Robert Bogden.

**GUESTS:** Dan Dreesmann and Pat Reisenauer

**1. MINUTES – November 14, 2005**

Motion to approve by L. Thomashow, 2nd by D. Clark; passed 6:0

**2. ANNOUNCEMENTS**

A) Pat Reisenauer will be visiting IBC occasionally and representing Dr. Diter Von Wettstein and Kulvinder Gill.

B) BSO will be joining Research Compliance Office on December 19, 2005.

C) On the application, page 2, a line was added stating 'research involving transgenic plants by CAHNRS and WSU Extension researchers must be routed through ARC prior to submittal to the IBC'.

D) IBC manual and Memorandum 13 are updated on the IBC website.

**(Note: The protocols were not reviewed in the order of the agenda).**

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Transcript-based Cloning of Genes* von Wettstein, D. 920

*Determining Photoperiodic and Thermoperiodic Responses*

**Primary Reviewer: L. Thomashow      Secondary Reviewer: S. Ristow**

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to **approve** by L. Thomashow, 2<sup>nd</sup> by S. Russell; passed 7:0.

2) *Barley Lines Expressing Lysozyme* von Wettstein, D. 922

*Or Lactoferrin in the Grain*

**Primary Reviewer: L. Thomashow      Secondary Reviewer: S. Ristow**

The Primary and secondary reviewers have minor comments on the application. The committee wanted a copy of the training program and copy of the approval from APHIS for approving the protocol.

The committee deferred the BAF and requested the following for approval:

1. Application:

- On page 3 of 12, section 2, under part G, need to use separate lines to fill out for each building. State clearly the location for field plot. Clarify what is housed in 507 and 12 PSB.
- On page 8, of 12, section 6, questions 5, 6 and 7 need more detail. Specifically for question 5, state how close these plots are to the neighbors. For question 7, clarify if the material from the field be autoclaved also? Are you destroying the buffer also?

2. Training program:

- Need to have approval or documentation of the training program for IBC records.

3. APHIS Approval

- Need APHIS approval letter for IBC approval and records.

Motion to defer pending clarifications suggested by the committee and re review by Primary reviewer and IBC Coordinator by L. Thomashow, 2<sup>nd</sup> by L. Herrmann; passed 7:0.

**B. Renewals**

1) *Membrane Function in Lipid Mutants of Caenorhabditis elegans*

*Browse, J.*

205

Primary Reviewer: J. Hogan

Secondary Reviewer: R. Bogden

The Primary reviewer had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

1. Application:

- On page 3 of 11, section 2, under G, for greenhouse 114, the room is not filled out. Is it 114? Could you give more details?
- On page 5 of 11, section 4, question 1, please elaborate what it means by "castor bean and others". You need to specify the 'others'.
- On page 5 of 11, section 4, question 3, please elaborate host and vector systems used and fill out the blanks below for host, vector, genes to be clones, DNA/RNA.
- On page 6 of 11, section 6, question 6, you have stated the answer as standard maintenance and disposal procedures. Please elaborate and specify the procedures.

Motion to defer pending more details on the BAF and re review by IBC Coordinator by J. Hogan, 2<sup>nd</sup> by L. Thomashow; passed 7:0.

2) *Natural Transmission of OPPV*

*Herrmann, L.*

806

Primary Reviewer: S. Russell

Secondary Reviewer: D. Bradway

Primary reviewer and the committee did not have any concerns over the protocol. (Dan Bradway was not there to vote. Since it was Lynn Herrmann's own protocol, she left the room during voting)

Motion to approve by S. Russell, 2<sup>nd</sup> by D. Clark; passed 6:0.

3) *Haemonchus Contortus*

*Jasmer, D.*

712

Primary Reviewer: L. Herrmann

Secondary Reviewer: J. Dahl

The Primary reviewer did not have any concerns. The committee requested a copy of revised abstract for approval.

Motion to defer pending revised abstract for IBC records and reviewed by IBC Coordinator by L. Herrmann, 2<sup>nd</sup> by S. Russell; passed 7:0.

**C. Modifications**

None

**2. BSL-2 BAF's**

**A. New Protocols**

1) *Detection and Sub typing of Bacteria  
Viruses*

*Call, D.* 923

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: L. Herrmann**

Secondary reviewer or the committee did not have any concerns over the protocol.

Motion to approve by L. Herrmann, 2<sup>nd</sup> by L. Thomashow; passed 7:0.

2) *Parental Effects on Children's Coping  
with Stress*

*Power, T.* 924

**Primary Reviewer: S. Russell**

**Secondary Reviewer: J. Hogan**

**3<sup>rd</sup>: M. Kluzik**

The reviewers did not have major concerns. J. Hogan requested for BSL-2 facility and BBP approval prior to the approval.

Motion to defer pending BSL-2 facility and BBP approval by S. Russell and 2<sup>nd</sup> by J. Hogan; passed 8:0. (Dan Bradway joined the meeting by telephone.)

3) *Regulation of Gonadotropin Gene  
Expression*

*Nilson, J.* 921

**Primary Reviewer: D. Bradway**

**Secondary Reviewer: J. Dahl**

The primary reviewer, D. Bradway joined the meeting by phone. He did not have major concerns with regards to the BAF. Mike informed the committee that BBP is approved and the only requirement is "eyewash" installation. It will take some time for the WAC approved eyes wash to be installed. The lab could have an interim eyewash plan. Mike will inspect the facility for "eyewash" requirements and let the IBC Coordinator know about this. The committee deferred the protocol until IBC Coordinator receives a notification from Mike Kluzik with regards to "eyewash" requirements approval.

Motion to defer pending notification from Mike Kluzik to IBC Coordinator with regards to "eyewash" requirements by D. Bradway and 2<sup>nd</sup> by L. Herrmann; passed 8:0. (Dan Bradway left the meeting)

2) *Detection and Sub typing of Bacteria  
Viruses*

*Call, D.* 923

**Primary Reviewer: J. Dahl**

**Secondary Reviewer: L. Herrmann**

Secondary reviewer or the committee did not have any concerns over the protocol.

Motion to approve by L. Herrmann, 2<sup>nd</sup> by L. Thomashow; passed 7:0.

**B. Renewals**

1) *Comparative Genomics*

*Call, D.* 817

**Primary Reviewer: L. Herrmann**

**Secondary Reviewer: J. Dahl**

Primary reviewer or the committee did not have any concerns over the protocol.

Motion to approve by L. Herrmann, 2<sup>nd</sup> by L. Thomashow; passed 7:0.

**C. Modifications**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

**1) *Functional Analysis of Human MutS Homologous Proteins, hMSH4 and hMSH5* Her, C. 772**

Originally reviewed on August 29, 2005:

- Jennifer Hogan gave an overview of the project. The committee felt that section 5 on the application should clarify the use of human cell line. Prior to the IBC meeting, PI contacted Mike Kluzik and was told by Mike that he needs to submit updated biosafety manual and include blood borne pathogen training. The PI also needs to fill out section 5 and delete section 3 on the application form. Motion to defer pending submission of updated biosafety manual with BBP training and completion of section 5 on the application and re reviewed by Malathi Jandhyala.
- 08/30/05: The PI submitted the BAF with section 5 completed. Need updated biosafety manual with BBP training.
- 10/18/05: Mike Kluzik communicated with PI regarding updating biosafety manual. Waiting to hear from the PI.
- 11/15/05: The PI has updated the manual with BBP training. The protocol was approved.

**2) *Improving Suicide Genes for Cancer Gene Therapy Engineering Enzymes for Anti-Tumor Suicide Gene Therapy* Black, M. 620**

Originally reviewed on November 14, 2005:

PI needs to give clarifications to the following:

- On the application, Section 4, need to clarify what type of containment level will be used
- On the application, the PI stated that "mammalian cells will be used". Need to clarify if these cells are human or otherwise.
- If these cells are human, need to make sure that BL-2 practices are followed and biosafety manual, and blood borne pathogen plan should be in place. Need to work with Mike Kluzik regarding these issues.
- Motion to defer pending clarifications suggested by the committee and re review by IBC Coordinator and Mike Kluzik (if the cells are from human cell line).
- 12/02/05: The PI has developed and adopted a BSL-2 biosafety manual with an appendix addressing the OSHA bloodborne pathogen requirements for established human cell lines. The protocol was approved.

## **7. Deferred BAF's**

### **1) *Pilot Study of Circadian Rhythm's, Sleep and Cytokines In Childhood Acute Lymphoblastic Leukemia (ALL)* Kruger, J. M. 905**

Originally reviewed on July 18, 2005:

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to defer pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.
- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.
- 12/12/05: Mike will contact the researchers regarding the clarification.

### **2) *High Resolution Ion Mobility Mass Spectrometry (IMMS) for Measuring and Monitoring Metabolomes* Hill, H. 917**

Originally reviewed on October 24, 2005:

- Dr. Hill's lab contact [REDACTED] sent the copy of biosafety manual to Chris Baylon on October 13, 2005. Chris Baylon sent an e-mail to the PI to address some concerns with regards to biosafety manual. Jennifer Hogan had questions with regards to transport plan of the samples. She communicated her concerns to the PI's lab contact [REDACTED]. [REDACTED] has responded in an e-mail. The secondary reviewer agreed with the comments of primary. The committee wanted a clarification on these points a) update the BBP with transport plan of the samples b) completed biosafety manual with revisions requested by Chris Baylon c) perchloric acid hood (Mike is working on it). Motion to defer pending clarifications to the reviewers' points mentioned above and re-reviewed by primary and secondary reviewers.
- 10/27/05: The PI's lab contact [REDACTED] submitted the manual with revisions. Chris Baylon approved the manual with revisions. Chris had the following questions for [REDACTED] a) Chris communicated that they do not have a record of a perchloric acid hood in Eastlick 390. Need to make sure if it is really a perchloric acid hood or just a normal fume hood in Eastlick 390. Chris also mentioned that this will not matter if the conditions he mentioned about not heating the acid or using large quantities are met. Use of a standard fume hood will be acceptable under these conditions. b) It is not clear if blood samples being transported from Eastlick to Troy will be disinfected before transporting. If not, Troy312 will need to be inspected as a BSL-2 lab as well as Eastlick 390. Eastlick 390 will need to be inspected for approval for use as a BSL-2 lab. Troy 312 will also need to be inspected if infectious agents will be used there. The PI needs to contact Chris Baylon to schedule inspections.
- 12/12/05: E-mail from Mike on December 2, 2005, BBP and BSL-2 biosafety manual have been reviewed and approved. As per the IBC motion, Mike e-mailed his recommendations to primary and secondary reviewers for their approval.

## **8. Old Business**

None

## **9. New Business**

A) Dave and Sandra addressed the need to have subcommittees' for diagnostic labs, teaching labs, farm related protocols and select agents' issues in the upcoming year.

**10. Adjournment**

Motion passed by L. Thomashow; passed 7:0. Meeting was adjourned at 2:20 PM.

**Next meeting will be on January 23, 2005 from 1:10 to 2:30 pm at Neill 416 in Pullman).**

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**January 23, 2006**  
**1:10-2:30 pm**  
**Neill Hall 416**

**IBC Members Present:** Sandra Ristow, Linda Thomashow, Hanu Pappu, John Dahl, Daniel Bradway, Lynn Herrmann, Dave Clark, Robert Bogden , and Steven Russell.

**IBC Members Absent:** Jennifer Hogan, and [REDACTED].

**IBC Staff Present:** Malathi Jandhyala

**IBC Invited Attendees:** Pat Reisenauer, Rob Corcoran, Lorraine McConnell and Mike Kluzik.

**1. MINUTES** – December 12, 2005

Motion to approve by **D. Clark**, 2nd by **H. Pappu**; passed 9:0

**2. ANNOUNCEMENTS**

A) Bio safety Officer, Lorraine McConnell was welcomed. She has joined the Research Compliance Office on December 19, 2005.

B) Dave Clark informed the committee about the inconsistencies in IBC roster on the President's website. The IBC roster will be representing IBC members only. The non-IBC members such as IBC staff and other attendees will be categorized into IBC staff and IBC invited attendees and will not be included in the IBC roster.

C) Sandra Ristow emphasized the need of recruiting more committee members for reviewing plant protocols to ease the burden on the current reviewers. She requested the members to let her know possible plant faculty that are interested in IBC membership.

D) Sandra Ristow informed the committee that she will be unavailable to attend the pre-IBC and IBC meeting in March and wanted to know if someone would be willing to be Interim IBC chair for March pre-IBC and IBC meeting. John Dahl is going to check his calendar and inform the IBC Coordinator.

E) IBC member Jennifer Hogan and her husband are blessed with a little baby boy, Kellan Sawyer on the 5<sup>th</sup> of January. Congratulations Jennifer!

**1. BSL-1 BAF's**

**A. New Protocols**

1) *Release Notification Letter di 05-035-14n Renewal and di von Wettstein,D.* 927  
*05-035-13n Beta glucanase, Chitinase Expression in Barley*

**Primary Reviewer:** L. Herrmann

**Secondary Reviewer:** D. Clark

Secondary reviewer requested the APHIS permits. The committee deferred the BAF and requested the following on the protocol:

- APHIS approval copy is needed for the IBC records.

Motion to defer pending APHIS approval copy by J. Hogan, 2<sup>nd</sup> by L. Thomashow; passed 9:0.

### **B. Renewals**

1) *Breeding and Genetics of Barley (WNP01006)* Ullrich, S. 797  
Primary Reviewer: D. Bradway Secondary Reviewer: J. Dahl

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by D. Bradway, 2<sup>nd</sup> by R. Bogden; passed 9:0.

2) *Control of Strawbreaker Foot Rot and Cephalosporium* Murray, T.D. 589  
*Stripe in Winter Wheat*  
Primary Reviewer: H. Pappu Secondary Reviewer: D. Clark

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by H. Pappu, 2<sup>nd</sup> by D. Bradway; passed 9:0.

3) *Development of Promoters and Antifungal Gene* Okubara, P. 795  
*Constructs to Combat Root Necrotrophic Pathogens of Barley and Wheat*  
Primary Reviewer: S. Russell Secondary Reviewer: J. Dahl  
Discussion:

The reviewers had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

#### **1. Application:**

- Need to check the right boxes on page 3 of 11, 5 of 11, (5 minor changes) and revised abstract. Need to do these six minor changes for approval.

Motion to defer pending 5 minor changes and revised abstract and re reviewed by IBC Coordinator by D. Bradway, 2<sup>nd</sup> by L. Herrmann; passed 9:0.

### **C. Modifications**

None

### **2. BSL-2 BAF's**

#### **A. New Protocols**

1) *At-Risk Population (s) for Salmonella Contamination and* Besser, T. E. 925  
*the Effects of Pre-Slaughter Hide Wash/Decontamination*  
Primary Reviewer: D. Bradway Secondary Reviewer: L. Herrmann

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by R. Bogden, 2<sup>nd</sup> by D. Bradway; passed 9:0.

2) *Bioimaging* Call, D. 926

Primary Reviewer: S. Ristow Secondary Reviewer: R. Bogden  
The reviewers had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

#### **1. Application:**

- On page 4 of 6, the biosafety level for host, vector and gene should be 2. IBC Coordinator needs to ask the PI and make the change on the form.



Motion to **defer** pending clarification and revision of biosafety level on page 4 of 6 by IBC Coordinator by R. Bogden, 2<sup>nd</sup> by L. Herrmann; passed 9:0.

3) *Mapping and Cloning the Gene (s) for Familial High Myopia* *Bejjani, B.* 928

**Primary Reviewer:** R. Bogden

**Secondary Reviewer:** S. Russell

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to **approve** by S. Russell, 2<sup>nd</sup> by J. Dahl; passed 9:0.

4) *Mapping and Cloning the Gene (S) for Keratoconus* *Bejjani, B.* 929

**Primary Reviewer:** D. Clark

**Secondary Reviewer:** S. Ristow

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to **approve** by R. Bogden, 2<sup>nd</sup> by L. Thomashow; passed 9:0.

**B. Renewals**

None

**C. Modifications**

None

**5. BSL-3 BAF's**

None

**6. Protocols approved in the interim**

1) *Membrane Function in Lipid Mutants of Caenorhabditis elegans* *Browse, J.* 205

Originally reviewed on December 12, 2005:

- The Primary reviewer had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following: a) On page 3 of 11, section 2, under G, for greenhouse 114, the room is not filled out. Is it 114? Could you give more details? b) On page 5 of 11, section 4, question 1, please elaborate what it means by "castor bean and others". You need to specify the 'others'. c) On page 5 of 11, section 4, question 3, please elaborate host and vector systems used and fill out the blanks below for host, vector, genes to be clones, DNA/RNA. d) On page 6 of 11, section 6, question 6, you have stated the answer as standard maintenance and disposal procedures. Please elaborate and specify the procedures. Motion to **defer** pending more details on the BAF and re review by IBC Coordinator.
- 12/14/05: The PI has taken care of the revisions on the BAF. The protocol was approved.

2) *Haemonchus Contortus*

*Jasmer, D.*

712

Originally reviewed on December 12, 2005:

- The Primary reviewer did not have any concerns. The committee requested a copy of revised abstract for approval. Motion to defer pending revised abstract for IBC records and reviewed by IBC Coordinator.
- 12/14/05: Received the abstract from PI. The protocol was approved.

3) *Regulation of Gonadotropin Gene Expression*

Nilson, J.

921

**Originally reviewed on December 12, 2005:**

- The primary reviewer, D. Bradway joined the meeting by phone. He did not have major concerns with regards to the BAF. Mike informed the committee that BBP is approved and the only requirement is "eyewash" installation. It will take some time for the WAC approved eyes wash to be installed. The lab could have an interim eyewash plan. Mike will inspect the facility for "eyewash" requirements and let the IBC Coordinator know about this. The committee deferred the protocol until IBC Coordinator receives a notification from Mike Kluzik with regards to "eyewash" requirements approval. Motion to defer pending notification to IBC Coordinator, from Mike Kluzik with regards to "eyewash" requirements.
- 12/14/05: Mike sent an e-mail to IBC Coordinator stating that the requirements for 'eyewash' were satisfied. The protocol was approved.

4) *Pilot Study of Circadian Rhythms, Sleep and Cytokines In Childhood Acute Lymphoblastic Leukemia (ALL)*

Kruger, J. M.

905

**Originally reviewed on July 18, 2005:**

- John and Lynn discussed the protocol. The lab personnel currently do not have blood borne pathogen training. There is no clarity with regard to the methods of measuring (if they are using BSL-2 cabinets) the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons. Motion to defer pending notifying the IBC regarding blood borne pathogen training and also clarifying the methods of measuring the pro-inflammatory cytokines IL-1 beta, TNF-alpha, and 15 other cytokines/chemokines/interferons.
- 8/23/05: As per Mike Kluzik's e-mail, although the BBP training has been completed, researchers are still working on clarifying the methods for measuring the pro-inflammatory cytokines.
- 12/12/05: Mike will contact the researchers regarding the clarification.
- 12/15/05: Dr. Kruger' lab contact provided the clarification for measuring the pro-inflammatory cytokines. Sandra reviewed the clarification and Okayed it. The protocol was approved.

**7. Deferred BAF's**

1) *High Resolution Ion Mobility Mass Spectrometry (IMMS) for Measuring and Monitoring Metabolomes*

Hill, H.

917

**Originally reviewed on October 24, 2005:**

- Dr. Hill's lab contact [REDACTED] sent the copy of biosafety manual to Chris Baylon on October 13, 2005. Chris Baylon sent an e-mail to the PI to address some concerns with regards to biosafety manual. Jennifer Hogan had questions with regards to transport plan of the samples. She communicated her concerns to the PI's lab contact [REDACTED]. [REDACTED] has responded in an e-mail. The secondary reviewer agreed with the comments of primary. The committee wanted a clarification on these points a) update the BBP with

transport plan of the samples b) completed biosafety manual with revisions requested by Chris Baylon c) perchloric acid hood (Mike is working on it). Motion to defer pending clarifications to the reviewers' points mentioned above and re-reviewed by primary and secondary reviewers.

- 10/27/05: The PI' lab contact [REDACTED] submitted the manual with revisions. Chris Baylon approved the manual with revisions. Chris had the following questions for [REDACTED] a) Chris communicated that they do not have a record of a perchloric acid hood in Eastlick 390. Need to make sure if it is really a perchloric acid hood or just a normal fume hood in Eastlick 390. Chris also mentioned that this will not matter if the conditions he mentioned about not heating the acid or using large quantities are met. Use of a standard fume hood will be acceptable under these conditions. b) It is not clear if blood samples being transported from Eastlick to Troy will be disinfected before transporting. If not, Troy312 will need to be inspected as a BSL-2 lab as well as Eastlick 390. Eastlick 390 will need to be inspected for approval for use as a BSL-2 lab. Troy 312 will also need to be inspected if infectious agents will be used there. The PI needs to contact Chris Baylon to schedule inspections.
- 12/12/05: E-mail from Mike on December 2, 2005, BBP and BSL-2 biosafety manual have been reviewed and approved. As per the IBC motion, Mike e-mailed his recommendations to primary and secondary reviewers for their approval.
- 01/13/06: Jennifer Hogan and John Dahl raised questions with regards to transport of samples and certification of biosafety cabinet in Dr. Lying Xun's Eastlick lab (384-390). Mike agreed that the cabinet needs to be certified in order to approve the protocol.

**2) Barley Lines Expressing Lysozyme  
Or Lactoferrin in the Grain**

*von Wettstein, D.* 922

**Originally reviewed on 12/12/05:**

- The Primary and secondary reviewers have minor comments on the application. The committee wanted a copy of the training program and copy of the approval from APHIS for approving the protocol. The committee deferred the BAF and requested the following for approval: 1. Application: a) On page 3 of 12, section 2, under part G, need to use separate lines to fill out for each building. State clearly the location for field plot. Clarify what is housed in 507 and 12 PSB. b) On page 8, of 12, section 6, questions 5, 6 and 7 need more detail. Specifically for question 5, state how close these plots are to the neighbors. For question 7, clarify if the material from the field be autoclaved also? Are you destroying the buffer also? 2. Training program: a) Need to have approval or documentation of the training program for IBC records. 3) APHIS Approval: a) Need APHIS approval letter for IBC approval and records. Motion to defer pending clarifications suggested by the committee and re review by Primary reviewer and IBC Coordinator
- 01/13/06: Dr. von Wettstein provided the clarifications and Linda Thomashow and Sandra Ristow were okay with the clarifications. APHIS approval is needed for approval. PI will forward the letters when he obtains them.

**3) Parental Effects on Children's Coping  
with Stress**

*Power, T.* 924

**Originally reviewed on 12/12/05:**

- The reviewers did not have major concerns. J. Hogan requested for BSL-2 facility and BBP approval prior to the approval. Motion to defer pending BSL-2 facility and BBP approval.

- 01/13/06: As per Tom's e-mail on December 13, 2005, they are working with Mike for BSL-2 and BBP approval.
- 01/23/06: Mike Kluzik gave an update on the protocol. He clarified and justified to the committee that the PIs' require BSL-1 lab with BSL-2 practices since they collect saliva without any traces of blood. The PIs' requested Mike to ask the committee if they can revise the BAF and submit as BL-1. The committee agreed to the request and suggested few changes and made a motion. On the application they need to indicate room # 613, need to change gloves between each sampling and finally it was suggested that the researchers should wear plain protective clothes to minimize stress which could be counter productive to the experiment. The protocol can be submitted and re reviewed by Mike, Malathi and Sandra. Motion was made (**R. Bogden**) with changes to protocol as suggested above and re reviewed by Mike Kluzik, Sandra Ristow and Malathi Jandhyala; 2<sup>nd</sup> by **D. Clark**. Passed 9:0.

#### **8. Old Business**

None

#### **9. New Business**

A) Biosafety Update from Lorraine McConnell:

1. Biosafety website developed that includes direct access to BAF and BAF amendment forms, biosafety directory, a researcher's guide to working with recombinant DNA (rDNA). Sections for Animal, Plant and Lab resources. Will be up as soon as IT finishes populating the site.
2. Training: Have developed lab based training for the website, new member IBC training, yearly IBC training for 2006, training for safety committees (currently meeting with safety committees as I am invited)
3. Have been preparing lab review checklists and noting ideas regarding how to best incorporate guidelines into existing forms, processes. job descriptions etc.
4. Results of Lab Review – Mike Kluzik (comparison of BAF and certified lab sites for BSL-2 & BSL-3 labs) has yielded interesting results. Some investigators are still unfamiliar with the BAF process. I have been educating PI's regarding these matters.

#### **10. Adjournment**

The meeting was called to adjourn by **L. Thomashow** at 2:15 pm.

**MINUTES**  
**WSU Institutional Biosafety Committee Meeting**  
**February 27, 2006**  
**1:10-2:30 pm**  
**Neill Hall 416**

**IBC Members Present:** Sandra Ristow (Chair), Linda Thomashow, Hanu Pappu, John Dahl, Daniel Bradway, Lynn Herrmann, Robert Bogden, Lorraine McConnell, [REDACTED] and Steven Russell.

**IBC Members Absent:** Jennifer Hogan, Joe Yenish, and Dave Clark.

**IBC Staff Present:** Malathi Jandhyala

**IBC Invited Attendees:** Pat Reisenauer, Rob Corcoran, and Mike Kluzik.

**1. MINUTES** – January 23, 2006

Motion to approve with minor edits by H. Pappu, 2nd by S. Russell; passed 10:0

**2. ANNOUNCEMENTS**

A) John Dahl will be the interim Chair for March Pre-IBC meeting and IBC meeting (March 20<sup>th</sup> and 27<sup>th</sup>)

B) Joe Yenish is officially appointed as member on the IBC committee.

**1. BSL-1 BAF's**

**A. New Protocols**

None

**B. Renewals**

None

**C. Modifications**

None

**2. BSL-2 BAF's**

**A. New Protocols**

1) *Ecology and Epidemiology of E.Coli O157:H7, Campylobacter spp., and Salmonella enterica in Cattle*

Hancock, D. 930

**Primary Reviewer:** D. Bradway

**Secondary Reviewer:** H. Pappu

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by R. Bogden, 2<sup>nd</sup> by L. Thomashow; passed 10:0.

2) *Function of MAP2D in Granulosa Cells*

Hunzicker-Dunn, M. 931

**Primary Reviewer:** L. Herrmann

**Secondary Reviewer:** R. Bogden

The reviewers had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

1. Application:

- On page 6 of 11, under question 2, Nature of inserted DNA sequences to be transferred, you have mentioned FOXO1. Please clarify what FOXO1 is.

2. EH & S issues:

- Bio safety cabinet and rooms need to be certified.

Motion to defer pending clarification about FOXO1 and biosafety cabinet and rooms' certification by L. Herrmann, 2<sup>nd</sup> by J. Dahl; passed 10:0.

3) *A Method for Sequestering Breast Cancer Cells and Interaction of Bone Cells with Ceramic Substrata*

Hosick, H. 932

Primary Reviewer: L. McConnell

Secondary Reviewer: S. Ristow

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by L. Herrmann, 2<sup>nd</sup> by L. Thomashow; passed 10:0.

4) *Physical and Chemical Interventions for Controlling Levels of Bacterial Food Borne Pathogens*

Kang, D. 933

Primary Reviewer: J. Dahl

Secondary Reviewer: [REDACTED]

The reviewers did not have any comments on the application. The committee deferred the BAF and requested more clarifications on the following:

1. EH & S issues:

- Bio safety cabinet needs to be certified.

Motion to defer pending certification of biosafety cabinet by L. Thomashow, 2<sup>nd</sup> by R. Bogden; passed 10:0.

5) *Influence of p21Cip1 on the Synergism Between c-myc And Pim-1 Using Retroviral Gene Targeting into Human Primary Fibroblast Cells*

Magnuson, N.S. 934

Primary Reviewer: H. Pappu

Secondary Reviewer: L. McConnell

Hanu had questions about the use of human fibroblast cells. Lorraine informed the committee that the PI wanted to use mouse NIH3T3 cell line in stead of human fibroblast cells in order to reduce the risk or working with the retrovirus system. The PI sent revised abstract and title. The revised title is "Influence of p21Cip1 on the synergism between c-myc and Pim-1 using retroviral gene targeting into mouse fibroblast cells NIH3T3". The committee deferred the BAF and requested more clarifications on the following:

1. EH & S issues:

- Bio safety cabinet needs to be certified.

Motion to defer pending certification of biosafety cabinet by L. McConnell, 2<sup>nd</sup> by L. Herrmann; passed 10:0.

### **B. Renewals**

1) *Gene knockout and signature-tagged mutagenesis of Flavobacterium psychrophilum*

Call, D. 813

**Primary Reviewer:** L. Thomashow

**Secondary Reviewer:** S. Russell

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by L. Thomashow, 2<sup>nd</sup> by L. Herrmann; passed 10:0.

2) *Gene knockouts in E. coli*

Call, D. 814

**Primary Reviewer:** L. Herrmann

**Secondary Reviewer:** D. Bradway

Primary and secondary reviewers did not have any concerns over the protocol.

Motion to approve by R. Bogden 2<sup>nd</sup> by L. Thomashow; passed 10:0.

### **C. Modifications**

None

### **5. BSL-3 BAF's**

None

### **6) Protocols approved under Emergency category:**

1) *Haemonchus Contortus*

Jasmer, D. 712

**Primary reviewer:** McConnell, L.

**Secondary Reviewer:** Ristow, S.

This emergency modification request was routed to the committee electronically on January 25, 2006.

#### **Comments:**

The PI needs to upgrade the lab facility to BL-2 (need to work with Mike and Lorraine) and identify the animal room numbers on the amendment and resubmit the amendment for re review by M. Kluzik and L. McConnell.

#### **Motion:**

S. Ristow recommended BAF # 712 approval be deferred until above comments have been addressed by the principal investigator and re-reviewed by the M. Kluzik and L. McConnell.

Second was made by D. Clark.

#### **Revisions:**

Doug Jasmer clarified the committee members' questions. Please find attached revised BAF amendment. Lorraine and Mike looked over the revised BAF amendment and did not have any concerns.

02/01/06: Protocol was approved.

### **7. Protocols approved in the interim**

1) *Development of Promoters and Antifungal Gene*

Okubara, P. 795

*Constructs to Combat Root Necrotrophic Pathogens of Barley and Wheat*

**Originally reviewed on January 23, 2006:**

The reviewers had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

- Need to check the right boxes on page 3 of 11, 5 of 11, (5 minor changes) and revised abstract. Need to do these six minor changes for approval. Motion to defer pending 5 minor changes and revised abstract and re reviewed by IBC Coordinator.
- 1/24/06: The PI has taken care of the revisions on the BAF. The protocol was **approved**.

2) *Bioimaging*

Call, D.

926

**Originally reviewed on January 23, 2006:**

The reviewers had minor comments on the application. The committee deferred the BAF and requested more clarifications on the following:

- On page 4 of 6, the biosafety level for host, vector and gene should be 2. IBC Coordinator needs to ask the PI and make the change on the form. Motion to defer pending clarification and revision of biosafety level on page 4 of 6 by IBC Coordinator.
- 1/24/06: The PI has taken care of the revisions on the BAF. The protocol was **approved**.

**8. Deferred BAF's**

1) *High Resolution Ion Mobility Mass Spectrometry (IMMS) for Hill, H.  
Measuring and Monitoring Metabolomes*

917

**Originally reviewed on October 24, 2005:**

- Dr. Hill's lab contact [REDACTED] sent the copy of biosafety manual to Chris Baylon on October 13, 2005. Chris Baylon sent an e-mail to the PI to address some concerns with regards to biosafety manual. Jennifer Hogan had questions with regards to transport plan of the samples. She communicated her concerns to the PI's lab contact [REDACTED]. [REDACTED] has responded in an e-mail. The secondary reviewer agreed with the comments of primary. The committee wanted a clarification on these points a) update the BBP with transport plan of the samples b) completed biosafety manual with revisions requested by Chris Baylon c) perchloric acid hood (Mike is working on it). Motion to defer pending clarifications to the reviewers' points mentioned above and re-reviewed by primary and secondary reviewers.
- 10/27/05: The PI' lab contact [REDACTED] submitted the manual with revisions. Chris Baylon approved the manual with revisions. Chris had the following questions for [REDACTED]: a) Chris communicated that they do not have a record of a perchloric acid hood in Eastlick 390. Need to make sure if is really a perchloric acid hood or just a normal fume hood in Eastlick 390. Chris also mentioned that this will not matter if the conditions he mentioned about not heating the acid or using large quantities are met. Use of a standard fume hood will be acceptable under these conditions. b) It is not clear if blood samples being transported from Eastlick to Troy will be disinfected before transporting. If not, Troy312 will need to be inspected as a BSL-2 lab as well as Eastlick 390. Eastlick 390 will need to be inspected for approval for use as a BSL-2 lab. Troy 312 will also need to be inspected if infectious agents will be used there. The PI needs to contact Chris Baylon to schedule inspections.
- 12/12/05: E-mail from Mike on December 2, 2005, BBP and BSL-2 biosafety manual have been reviewed and approved. As per the IBC motion, Mike e-mailed his recommendations to primary and secondary reviewers for their approval.
- 01/13/06: Jennifer Hogan and John Dahl raised questions with regards to transport of samples and certification of biosafety cabinet in Dr. Lying Xun's Eastlick lab (384-390). Mike agreed that the cabinet needs to be certified in order to approve the protocol.
- 02/27/06: Need bio safety certification.



2) *Barley Lines Expressing Lysozyme  
Or Lactoferrin in the Grain*

von Wettstein, D. 922

**Originally reviewed on 12/12/05:**

- The Primary and secondary reviewers have minor comments on the application. The committee wanted a copy of the training program and copy of the approval from APHIS for approving the protocol. The committee deferred the BAF and requested the following for approval: 1. Application: a) On page 3 of 12, section 2, under part G, need to use separate lines to fill out for each building. State clearly the location for field plot. Clarify what is housed in 507 and 12 PSB. b) On page 8, of 12, section 6, questions 5, 6 and 7 need more detail. Specifically for question 5, state how close these plots are to the neighbors. For question 7, clarify if the material from the field be autoclaved also? Are you destroying the buffer also? 2. Training program: a) Need to have approval or documentation of the training program for IBC records. 3) APHIS Approval: a) Need APHIS approval letter for IBC approval and records. Motion to defer pending clarifications suggested by the committee and re review by Primary reviewer and IBC Coordinator
- 01/13/06: Dr. von Wettstein provided the clarifications and Linda Thomashow and Sandra Ristow were okay with the clarifications. APHIS approval is needed for approval. PI will forward the letters when he obtains them.
- 02/27/06: Need to receive APHIS permit.

3) *Parental Effects on Children's Coping  
with Stress*

Power, T. 924

**Originally reviewed on 12/12/05:**

- The reviewers did not have major concerns. J. Hogan requested for BSL-2 facility and BBP approval prior to the approval. Motion to defer pending BSL-2 facility and BBP approval.
- 01/13/06: As per Tom's e-mail on December 13, 2005, they are working with Mike for BSL-2 and BBP approval.
- 01/23/06: Mike Kluzik gave an update on the protocol. He clarified and justified to the committee that the PIs' require BSL-1 lab with BSL-2 practices since they collect saliva without any traces of blood. The PIs' requested Mike to ask the committee if they can revise the BAF and submit as BL-1. The committee agreed to the request and suggested few changes and made a motion. On the application they need to indicate room # 613, need to change gloves between each sampling and finally it was suggested that the researchers should wear plain protective clothes to minimize stress which could be counter productive to the experiment. The protocol can be submitted and re reviewed by Mike, Malathi and Sandra. Motion was made (R. Bogden) with changes to protocol as suggested above and re reviewed by Mike Kluzik, Sandra Ristow and Malathi Jandhyala; 2<sup>nd</sup> by D. Clark. Passed 9:0.
- 02/27/06: Mike will contact the PI.
- 02/28/06: Malathi made changes on the protocol and sent the revisions to Mike and Sandra. Mike approved the changes and also approved the BBP exposure control plan.

4) *Release Notification Letter di 05-035-14n Renewal and di  
05-035-13n Beta glucanase, Chitinase Expression in Barley*  
**Originally reviewed on January 23, 2006:**

von Wettstein, D. 927

- Secondary reviewer requested the APHIS permits. The committee deferred the BAF and requested the following on the protocol: APHIS approval copy is needed for the IBC records. Motion to defer pending APHIS approval copy.
- 02/27/06: Need to receive APHIS permit.

## **9. Biosafety Program Update**

**NOTE from the BSO:** I felt that last month it took a lot of time at the end of the meeting to review biosafety activities. I want to share information without burdening the meeting. To that end the printed agenda you receive with your IBC packet each month will include a section entitled Biosafety Update, (see below).

1. Tri-level IBC reviews process. BSO will act as the tertiary reviewer for IBC protocols.
2. Draft biosafety brochure has been developed, (see included copy in your IBC packet)
3. Working with Regional EH&S to meet off-site biosafety needs. Lezlie Couch the Regional EH&S coordinator is assisting by developing off-site biosafety directories to be posted on the Biosafety website.
4. Facility checklists developed directly from NIH and BMBL have been provided to Mike Kluzik, EH&S for a resource when performing facility inspections where biological materials are utilized.
5. Protocol checklists have been developed directly from NIH and BMBL as a resource for the BSO when assisting investigators with their Biosafety Manuals.
6. The Biosafety Manual Template is under review. When the update is complete the new Manual template will be available on the Biosafety website:  
[www.bio-safety.wsu.edu/biosafety](http://www.bio-safety.wsu.edu/biosafety)
7. Three different drafts of a teaching activities registration form have been developed for subcommittee review and recommendations.
8. BSO meeting with past IBC Chairs, Faculty, Safety Committees, and Technicians to gather insights and suggestions for Biosafety needs. If you would like to be included in this process or know someone or some group that is interested please let me know, ([lormcc@wsu.edu](mailto:lormcc@wsu.edu)) 335-4462
9. IBC audit procedure set up. To ensure database accuracy and to verify BAF activity in BSL-2 & BSL-3 facilities.

## **10. Old Business**

None

## **11. New Business**

a) WSU biosafety program brochure:

Lorraine McConnell developed biosafety brochure and will distribute the brochure in various departments (faculty, staff and graduate students). Lorraine asked the committee if they have any recommendations on the brochure and the committee did not have any.

b) Letter concerning GMO plant waste disposal:

The committee tabled the letter and recommended to discuss with Dave Clark (Research Compliance Officer) and Jim Petersen (Vice Provost of Research). The motion was made by L. Thomashow and second was made by R. Bogden. Motion passed 10:0

## **12. Adjournment**

The meeting was called to adjourn by L. Thomashow at 2:15 pm.